CA2614392A1 - Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism - Google Patents
Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism Download PDFInfo
- Publication number
- CA2614392A1 CA2614392A1 CA002614392A CA2614392A CA2614392A1 CA 2614392 A1 CA2614392 A1 CA 2614392A1 CA 002614392 A CA002614392 A CA 002614392A CA 2614392 A CA2614392 A CA 2614392A CA 2614392 A1 CA2614392 A1 CA 2614392A1
- Authority
- CA
- Canada
- Prior art keywords
- glycoprotein
- dye
- efflux
- cells
- pump inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 title claims abstract description 437
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 title claims abstract description 287
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 107
- 238000011282 treatment Methods 0.000 title claims abstract description 78
- 201000011510 cancer Diseases 0.000 title claims description 69
- 230000001747 exhibiting effect Effects 0.000 title claims description 8
- 230000007246 mechanism Effects 0.000 title description 5
- 230000004913 activation Effects 0.000 title description 4
- IHOVFYSQUDPMCN-DBEBIPAYSA-N chembl444172 Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1[C@@H]1C2=CC=CC=C2[C@H]2C(F)(F)[C@H]2C2=CC=CC=C12 IHOVFYSQUDPMCN-DBEBIPAYSA-N 0.000 claims abstract description 139
- 229950005752 zosuquidar Drugs 0.000 claims abstract description 139
- 238000000034 method Methods 0.000 claims abstract description 132
- 230000014509 gene expression Effects 0.000 claims abstract description 111
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 61
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 57
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 57
- 208000032839 leukemia Diseases 0.000 claims abstract description 29
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 157
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims description 154
- 239000003112 inhibitor Substances 0.000 claims description 123
- 238000003556 assay Methods 0.000 claims description 113
- 239000003814 drug Substances 0.000 claims description 90
- 229940124597 therapeutic agent Drugs 0.000 claims description 58
- 239000000758 substrate Substances 0.000 claims description 49
- 238000009825 accumulation Methods 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 30
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 28
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 27
- 229960000975 daunorubicin Drugs 0.000 claims description 26
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims description 26
- -1 thioperidone Chemical compound 0.000 claims description 25
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 24
- 206010025323 Lymphomas Diseases 0.000 claims description 15
- 229960001722 verapamil Drugs 0.000 claims description 13
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 12
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 12
- LGGHDPFKSSRQNS-UHFFFAOYSA-N Tariquidar Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC(OC)=C(OC)C=C3C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN=C21 LGGHDPFKSSRQNS-UHFFFAOYSA-N 0.000 claims description 11
- 229950005890 tariquidar Drugs 0.000 claims description 11
- NFIXBCVWIPOYCD-UHFFFAOYSA-N N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 claims description 10
- 229950007967 tesmilifene Drugs 0.000 claims description 10
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 9
- 108010036949 Cyclosporine Proteins 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 9
- 229960004679 doxorubicin Drugs 0.000 claims description 9
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 9
- 229960001156 mitoxantrone Drugs 0.000 claims description 9
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 9
- 229960003171 plicamycin Drugs 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 229940123237 Taxane Drugs 0.000 claims description 8
- 241000863480 Vinca Species 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 8
- 229960004528 vincristine Drugs 0.000 claims description 8
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 8
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 8
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 7
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 7
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 7
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 7
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 7
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 7
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 7
- 229960001904 epirubicin Drugs 0.000 claims description 7
- 229960005420 etoposide Drugs 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 229960000908 idarubicin Drugs 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 7
- 229960001278 teniposide Drugs 0.000 claims description 7
- 229960003048 vinblastine Drugs 0.000 claims description 7
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 7
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 6
- 108010092160 Dactinomycin Proteins 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 6
- 229960001265 ciclosporin Drugs 0.000 claims description 6
- 229960000640 dactinomycin Drugs 0.000 claims description 6
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 6
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 6
- 229960004166 diltiazem Drugs 0.000 claims description 6
- 229940080856 gleevec Drugs 0.000 claims description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 6
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 6
- 229960002431 trimipramine Drugs 0.000 claims description 6
- 229960004355 vindesine Drugs 0.000 claims description 6
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 6
- 229960002066 vinorelbine Drugs 0.000 claims description 6
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 229930105110 Cyclosporin A Natural products 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 238000003365 immunocytochemistry Methods 0.000 claims description 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 208000002774 Paraproteinemias Diseases 0.000 claims description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 4
- 230000003556 anti-epileptic effect Effects 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 239000000480 calcium channel blocker Substances 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 3
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 claims description 3
- WAVYHSURRZBQKO-UHFFFAOYSA-N 1-cyclohexyl-4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butan-1-one Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCC(=O)C1CCCCC1 WAVYHSURRZBQKO-UHFFFAOYSA-N 0.000 claims description 3
- PIKMDZDCXCAPEF-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-(3,4-dimethoxyphenyl)ethanol Chemical compound C1=C(OC)C(OC)=CC=C1C(O)CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 PIKMDZDCXCAPEF-UHFFFAOYSA-N 0.000 claims description 3
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 claims description 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 3
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 3
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 3
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 3
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 3
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 3
- 229940009456 adriamycin Drugs 0.000 claims description 3
- 229960002478 aldosterone Drugs 0.000 claims description 3
- 229960001830 amprenavir Drugs 0.000 claims description 3
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical group C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 3
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical group C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 claims description 3
- 229960003665 bepridil Drugs 0.000 claims description 3
- 229950008548 bisantrene Drugs 0.000 claims description 3
- 239000002371 cardiac agent Substances 0.000 claims description 3
- 229960001653 citalopram Drugs 0.000 claims description 3
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 3
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 3
- 229960005156 digoxin Drugs 0.000 claims description 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 3
- 229960002602 fendiline Drugs 0.000 claims description 3
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims description 3
- 229960000326 flunarizine Drugs 0.000 claims description 3
- 229960002690 fluphenazine Drugs 0.000 claims description 3
- 229960003878 haloperidol Drugs 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 238000003364 immunohistochemistry Methods 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 229960001936 indinavir Drugs 0.000 claims description 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 3
- 229950007692 lomerizine Drugs 0.000 claims description 3
- 229960004525 lopinavir Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 claims description 3
- 229960000884 nelfinavir Drugs 0.000 claims description 3
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 3
- 229960001783 nicardipine Drugs 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 150000002990 phenothiazines Chemical class 0.000 claims description 3
- 229960002036 phenytoin Drugs 0.000 claims description 3
- 229960001989 prenylamine Drugs 0.000 claims description 3
- 229960001852 saquinavir Drugs 0.000 claims description 3
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 3
- 229950004117 secoverine Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
- 229960001967 tacrolimus Drugs 0.000 claims description 3
- MXFWWQICDIZSOA-UHFFFAOYSA-N talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003658 talinolol Drugs 0.000 claims description 3
- 229950005687 tamolarizine Drugs 0.000 claims description 3
- 229960002784 thioridazine Drugs 0.000 claims description 3
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 3
- 229960003991 trazodone Drugs 0.000 claims description 3
- 229960005294 triamcinolone Drugs 0.000 claims description 3
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 3
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 claims description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960000836 amitriptyline Drugs 0.000 claims description 2
- 238000003255 drug test Methods 0.000 claims description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 229960000311 ritonavir Drugs 0.000 claims description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 abstract description 8
- 230000036210 malignancy Effects 0.000 abstract description 8
- 239000000975 dye Substances 0.000 description 70
- 230000006870 function Effects 0.000 description 45
- 230000000694 effects Effects 0.000 description 33
- 239000000203 mixture Substances 0.000 description 33
- 235000002639 sodium chloride Nutrition 0.000 description 28
- 230000036457 multidrug resistance Effects 0.000 description 25
- 238000009472 formulation Methods 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 21
- 238000001990 intravenous administration Methods 0.000 description 19
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 16
- 229960000684 cytarabine Drugs 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 238000001802 infusion Methods 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 238000011269 treatment regimen Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 11
- 230000000977 initiatory effect Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000002405 diagnostic procedure Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- VZUFSMBGWBLOCB-UHFFFAOYSA-N C3-oxacyanine cation Chemical compound O1C2=CC=CC=C2[N+](CC)=C1C=CC=C1N(CC)C2=CC=CC=C2O1 VZUFSMBGWBLOCB-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 229950010938 valspodar Drugs 0.000 description 8
- 108010082372 valspodar Proteins 0.000 description 8
- 206010059866 Drug resistance Diseases 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003380 propellant Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- CGVWPQOFHSAKRR-NDEPHWFRSA-N biricodar Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 CGVWPQOFHSAKRR-NDEPHWFRSA-N 0.000 description 3
- 229950005124 biricodar Drugs 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 230000000174 oncolytic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000012896 Statistical algorithm Methods 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003034 chemosensitisation Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 201000002687 childhood acute myeloid leukemia Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical class C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 description 1
- SVJMLYUFVDMUHP-MGBGTMOVSA-N (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[3-(4,4-diphenyl-1-piperidinyl)propyl] ester O3-methyl ester Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-MGBGTMOVSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- UPZKDDJKJWYWHQ-UHFFFAOYSA-N 2-(3-azaniumyl-6-iminoxanthen-9-yl)benzoate Chemical compound C=12C=CC(=N)C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O UPZKDDJKJWYWHQ-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 201000011057 Breast sarcoma Diseases 0.000 description 1
- FIZZUEJIOKEFFZ-UHFFFAOYSA-M C3-oxacyanine Chemical compound [I-].O1C2=CC=CC=C2[N+](CC)=C1C=CC=C1N(CC)C2=CC=CC=C2O1 FIZZUEJIOKEFFZ-UHFFFAOYSA-M 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000035561 Leukaemic infiltration brain Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Chemical class 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 229940124675 anti-cancer drug Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000006114 chemosensitizer Substances 0.000 description 1
- 230000005929 chemotherapeutic response Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229940107841 daunoxome Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229950002422 dexniguldipine Drugs 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.
Description
TREATMENT OF CANCER PATIENTS EXHIBITING ACTIVATION
OF THE P-GLYCOPROTEIN EFFLUX PUMP MECHANISM
RELATED APPLICATION
This application claims priority to U.S. Provisional Application No.
60/696,913 filed July 6, 2005, U.S. Application No. 11/418,399 filed May 3, 2006, U.S.
Application No. 11/417,984 filed May 3, 2006, U.S. Application No. 11/418,323 filed May 3, 2006, and to U.S. Provisional Application No. 60/726,827 filed October 14, 2005, which are expressly incorporated by reference herein in their entirety, and which are hereby made a part of this specification.
FIELD OF THE INVENTION
The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.
BACKGROUND OF THE INVENTION
The field of oncology is in the midst of a major evolution. In the past, the treatment of cancer has been dominated by empiric, "one-size-fits-all"
treatments based on types and stages of tumors. Toxic chemotherapy drugs have dominated the treatment landscape despite a very low cure rate, particularly against the most common cancers and those with known metastatic disease.
Now, treatments in development are targeted against specific proteins. Such targeting is based on a more robust knowledge of cancer mechanisms, which often crosses over many tumor types. These treatments are designed to work in defined subsets of patients, typically based on expression and function of the target protein rather than the type of tumor, and often in combination with standard chemotherapies. Advances in the molecular analysis of cancers will enable the identification of such susbsets of patients and the coupling of targeted therapeutics to novel diagnostic approaches.
The future of oncology lies in defining the disease in molecular terms (i.e., genetics, genomics, proteomics) and tailoring therapies according to individual tumor and normal cell properties. This new paradigm will predetermine likely responders, assess responses earlier, and adjust treatment based on continued molecular analyses of tumors.
Drug resistance is one of the most difficult problems that must be overcome in order to achieve successful treatment of human tuinors with chemotherapy.
Clinically, drug resistance, a characteristic of intrinsically resistant tumors (for example, colon, renal, and pancreas), may be evident at the onset of therapy. Alternatively, acquired drug resistance results when tumors initially respond to therapy but become refractory to subsequent treatments. Once a tumor has acquired resistance to a specific chemotherapeutic agent, it is common to observe collateral resistance to other structurally similar agents. The cellular mechanisms of drug resistance include apoptosis, drug uptake, DNA repair, altered drug targets, drug sequestration, detoxification, and efflux pumps (see, e.g., Dalton W.S. Semin. Oncol. 20:60, 1993).
Multidrug resistance (MDR), the ability of cancer cells to become resistant to the agent(s) actively used for therapy as well as other drugs that are structurally and functionally unrelated, is a particularly insidious form of drug resistance.
This form of drug resistance is discussed in greater detail in Kuzmich et al., "Detoxification Mechanisms and Tumor Cell Resistance to Anticancer Drugs," particularly section VII
"The Multidrug-Resistant Phenqtype (MDR)," Medical Research Reviews, Vol. 11, No.
OF THE P-GLYCOPROTEIN EFFLUX PUMP MECHANISM
RELATED APPLICATION
This application claims priority to U.S. Provisional Application No.
60/696,913 filed July 6, 2005, U.S. Application No. 11/418,399 filed May 3, 2006, U.S.
Application No. 11/417,984 filed May 3, 2006, U.S. Application No. 11/418,323 filed May 3, 2006, and to U.S. Provisional Application No. 60/726,827 filed October 14, 2005, which are expressly incorporated by reference herein in their entirety, and which are hereby made a part of this specification.
FIELD OF THE INVENTION
The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.
BACKGROUND OF THE INVENTION
The field of oncology is in the midst of a major evolution. In the past, the treatment of cancer has been dominated by empiric, "one-size-fits-all"
treatments based on types and stages of tumors. Toxic chemotherapy drugs have dominated the treatment landscape despite a very low cure rate, particularly against the most common cancers and those with known metastatic disease.
Now, treatments in development are targeted against specific proteins. Such targeting is based on a more robust knowledge of cancer mechanisms, which often crosses over many tumor types. These treatments are designed to work in defined subsets of patients, typically based on expression and function of the target protein rather than the type of tumor, and often in combination with standard chemotherapies. Advances in the molecular analysis of cancers will enable the identification of such susbsets of patients and the coupling of targeted therapeutics to novel diagnostic approaches.
The future of oncology lies in defining the disease in molecular terms (i.e., genetics, genomics, proteomics) and tailoring therapies according to individual tumor and normal cell properties. This new paradigm will predetermine likely responders, assess responses earlier, and adjust treatment based on continued molecular analyses of tumors.
Drug resistance is one of the most difficult problems that must be overcome in order to achieve successful treatment of human tuinors with chemotherapy.
Clinically, drug resistance, a characteristic of intrinsically resistant tumors (for example, colon, renal, and pancreas), may be evident at the onset of therapy. Alternatively, acquired drug resistance results when tumors initially respond to therapy but become refractory to subsequent treatments. Once a tumor has acquired resistance to a specific chemotherapeutic agent, it is common to observe collateral resistance to other structurally similar agents. The cellular mechanisms of drug resistance include apoptosis, drug uptake, DNA repair, altered drug targets, drug sequestration, detoxification, and efflux pumps (see, e.g., Dalton W.S. Semin. Oncol. 20:60, 1993).
Multidrug resistance (MDR), the ability of cancer cells to become resistant to the agent(s) actively used for therapy as well as other drugs that are structurally and functionally unrelated, is a particularly insidious form of drug resistance.
This form of drug resistance is discussed in greater detail in Kuzmich et al., "Detoxification Mechanisms and Tumor Cell Resistance to Anticancer Drugs," particularly section VII
"The Multidrug-Resistant Phenqtype (MDR)," Medical Research Reviews, Vol. 11, No.
2, 185-217, particularly 208-213 (1991); and in Georges et al., "Multidrug Resistance and Chemosensitization: Therapeutic Implications for Cancer Chemotherapy,"
Advances in Pharmacology, Vol. 21, 185-220 (1990).
Although MDR may be caused by a variety of factors, one of the most prevalent forms of MDR is the type associated with overexpression of P-glycoprotein (P-gp). P-gp is a member of a superfamily of membrane proteins, termed adenosine triphosphate (ATP)-binding cassette (ABC) proteins, which behave as ATP-dependent transporters and/or ion channels for a wide variety of hydrophobic substrates. P-gp is a multiple transmembrane-spanning glycoprotein. Transfection experiments with the P-gp gene (MDR1, or ABCBI) have conferred MDR to drug-sensitive tumor cells by providing an energy-dependent efflux pump that lowers the intracellular concentration of the cytotoxic agent, thereby allowing survival of the cell.
P-gp is expressed in normal biliary canaliculi of the liver, the adrenal cortex and proximal tubules of the kidney, and intestinal epithelia including the columnar cells of the large and small intestines; capillary endothelial cells of brain, testis, and placenta; and in the hematopoietic stem cells of bone marrow. It possesses excretory, protective, and barrier functions. P-gp is constitutively expressed or selected in many human cancers, and confers resistance to therapeutic agents including anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone), vincas (e.g., vincristine, vinblastine, vinorelbine, vindesine), Topoisomerase-II inhibitors (e.g, etoposide, teniposide), taxanes (e.g., paclitaxel, docetaxel), and others (e.g., Gleevec, Mylotarg, dactinomycin, mithramycin).
The relative promiscuity of drug transport by P-gp and other MDR-associated transporters inspired a wide search for compounds that would not be cytotoxic themselves but would inhibit MDR transport. The initial demonstration of verapamil as a P-gp inhibitor was followed by many additional compounds reported to inhibit drug transport and thus sensitize MDR cells to chemotherapeutic drugs. Variously called chemosensitizers, MDR reversal agents, modulators, or converters, these 'first generation' MDR drugs included compounds of diverse structure and function such as calcium channel blockers (e.g., verapamil), immunosuppressants (e.g., cyclosporin A), antibiotics (e.g., erythromycin), antimalarials (e.g., quinine), and others (e.g., biricodar, tariquidar, valspodar).
First generation MDR drugs were not specifically developed for inhibiting MDR.
They often had other pharmacological activities, as well as a relatively low affinity for MDR transporters and thus were limited in application. For example, P-gp has a low affinity for verapamil, thus requiring cardiotoxic levels for full modulator activity. In spite of the fact that only low serum levels could be obtained in a Phase II
trial, 5 of 22 patients responded to a combination of verapamil and VAI) (vincristine, doxorubicin, and dexamethasone). Four of the responders had elevated P-gp expression and function.
Thus, verapamil has demonstrated some clinical utility in overcoming drug resistance.
Cyclosporin A alters the pharmacokinetics of coadministered cytotoxic agents, resulting in significantly increased exposure to the oncolytic, thus confounding the interpretation of clinical trials.
Further characterization of the P-gp pharmacophore led to the identification of 'second generation' modulators based on the first generation but specifically selected or designed to reduce the side effects of the latter by eliminating their non-MDR
pharmacological actions. Compounds such as the R-enantiomers of verapamil (R-verapamil) and dexniguldipine did not fare any better as MDR drugs in clinical studies, most likely because their affinity towards P-gp still fell short of producing significant inhibition of MDR in vivo at tolerable doses.
A more promising second generation modulator with a higher affinity towards P-gp was valspodar, a non-immunosuppressive cyclosporin D derivative. While early trials were encouraging, further work revealed significant pharmacokinetic interactions with several anticancer drugs. Although discontinued by Novartis, valspodar was studied in a Phase III study in elderly patients with acute myelogenous leulcemia.
Enrollment in the valspodar arm was halted due to excessive early mortality, most likely due to the PK
interactions. Although the number of patients was limited, patients in the control arm wllose pretreatment cells exhibited valspodar-modulated dye efflux in vitro (n = 22) had worse outcomes than those without efflux (n = 11) (complete remission, nonresponse, and death rates of 41%, 41%, and 18%, compared with 91%, 9%, and 0%; P = 0.03), but with valspodar outcomes were nearly identical (Baer 2002). Moreover, for patients with valspodar-modulated efflux, median disease-free survival was 5 months in the control arm and 14 months with valspodar (P = 0.07).
A second generation MDR modulator with activity against both P-gp and MRP 1 (another ABC transporter associated with multidrug resistance) was biricodar.
Vertex studied the agent in multiple Phase II studies of soft tissue sarcomas, ovarian cancer, small cell lung cancer, and others. However, biricodar and valspodar are both substrates for the P450 isoenzyme 3A4. Competition between cytotoxic agents and the P-gp inhibitors for cytochrome P450 3A4 resulted in unpredictable PK interactions and resulted in increased serum concentrations of cytoxics and, therefore, greater toxicity to the patient. A common response of clinical researchers has been to reduce the dose of the cytotoxic agents. However, the PK interactions are unpredictable and cannot be determined in advance. As a result, cytotoxic serum levels were either too high resulting in excessive toxicity or too low resulting in decreased efficacy. In addition to inhibiting P-gp, many of the second generation modulators function as substrates for other transporters, particularly the ABC family, inhibition of which could lessen the ability of normal, healthy cells to protect themselves from the cytotoxic agents.
Advances in Pharmacology, Vol. 21, 185-220 (1990).
Although MDR may be caused by a variety of factors, one of the most prevalent forms of MDR is the type associated with overexpression of P-glycoprotein (P-gp). P-gp is a member of a superfamily of membrane proteins, termed adenosine triphosphate (ATP)-binding cassette (ABC) proteins, which behave as ATP-dependent transporters and/or ion channels for a wide variety of hydrophobic substrates. P-gp is a multiple transmembrane-spanning glycoprotein. Transfection experiments with the P-gp gene (MDR1, or ABCBI) have conferred MDR to drug-sensitive tumor cells by providing an energy-dependent efflux pump that lowers the intracellular concentration of the cytotoxic agent, thereby allowing survival of the cell.
P-gp is expressed in normal biliary canaliculi of the liver, the adrenal cortex and proximal tubules of the kidney, and intestinal epithelia including the columnar cells of the large and small intestines; capillary endothelial cells of brain, testis, and placenta; and in the hematopoietic stem cells of bone marrow. It possesses excretory, protective, and barrier functions. P-gp is constitutively expressed or selected in many human cancers, and confers resistance to therapeutic agents including anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone), vincas (e.g., vincristine, vinblastine, vinorelbine, vindesine), Topoisomerase-II inhibitors (e.g, etoposide, teniposide), taxanes (e.g., paclitaxel, docetaxel), and others (e.g., Gleevec, Mylotarg, dactinomycin, mithramycin).
The relative promiscuity of drug transport by P-gp and other MDR-associated transporters inspired a wide search for compounds that would not be cytotoxic themselves but would inhibit MDR transport. The initial demonstration of verapamil as a P-gp inhibitor was followed by many additional compounds reported to inhibit drug transport and thus sensitize MDR cells to chemotherapeutic drugs. Variously called chemosensitizers, MDR reversal agents, modulators, or converters, these 'first generation' MDR drugs included compounds of diverse structure and function such as calcium channel blockers (e.g., verapamil), immunosuppressants (e.g., cyclosporin A), antibiotics (e.g., erythromycin), antimalarials (e.g., quinine), and others (e.g., biricodar, tariquidar, valspodar).
First generation MDR drugs were not specifically developed for inhibiting MDR.
They often had other pharmacological activities, as well as a relatively low affinity for MDR transporters and thus were limited in application. For example, P-gp has a low affinity for verapamil, thus requiring cardiotoxic levels for full modulator activity. In spite of the fact that only low serum levels could be obtained in a Phase II
trial, 5 of 22 patients responded to a combination of verapamil and VAI) (vincristine, doxorubicin, and dexamethasone). Four of the responders had elevated P-gp expression and function.
Thus, verapamil has demonstrated some clinical utility in overcoming drug resistance.
Cyclosporin A alters the pharmacokinetics of coadministered cytotoxic agents, resulting in significantly increased exposure to the oncolytic, thus confounding the interpretation of clinical trials.
Further characterization of the P-gp pharmacophore led to the identification of 'second generation' modulators based on the first generation but specifically selected or designed to reduce the side effects of the latter by eliminating their non-MDR
pharmacological actions. Compounds such as the R-enantiomers of verapamil (R-verapamil) and dexniguldipine did not fare any better as MDR drugs in clinical studies, most likely because their affinity towards P-gp still fell short of producing significant inhibition of MDR in vivo at tolerable doses.
A more promising second generation modulator with a higher affinity towards P-gp was valspodar, a non-immunosuppressive cyclosporin D derivative. While early trials were encouraging, further work revealed significant pharmacokinetic interactions with several anticancer drugs. Although discontinued by Novartis, valspodar was studied in a Phase III study in elderly patients with acute myelogenous leulcemia.
Enrollment in the valspodar arm was halted due to excessive early mortality, most likely due to the PK
interactions. Although the number of patients was limited, patients in the control arm wllose pretreatment cells exhibited valspodar-modulated dye efflux in vitro (n = 22) had worse outcomes than those without efflux (n = 11) (complete remission, nonresponse, and death rates of 41%, 41%, and 18%, compared with 91%, 9%, and 0%; P = 0.03), but with valspodar outcomes were nearly identical (Baer 2002). Moreover, for patients with valspodar-modulated efflux, median disease-free survival was 5 months in the control arm and 14 months with valspodar (P = 0.07).
A second generation MDR modulator with activity against both P-gp and MRP 1 (another ABC transporter associated with multidrug resistance) was biricodar.
Vertex studied the agent in multiple Phase II studies of soft tissue sarcomas, ovarian cancer, small cell lung cancer, and others. However, biricodar and valspodar are both substrates for the P450 isoenzyme 3A4. Competition between cytotoxic agents and the P-gp inhibitors for cytochrome P450 3A4 resulted in unpredictable PK interactions and resulted in increased serum concentrations of cytoxics and, therefore, greater toxicity to the patient. A common response of clinical researchers has been to reduce the dose of the cytotoxic agents. However, the PK interactions are unpredictable and cannot be determined in advance. As a result, cytotoxic serum levels were either too high resulting in excessive toxicity or too low resulting in decreased efficacy. In addition to inhibiting P-gp, many of the second generation modulators function as substrates for other transporters, particularly the ABC family, inhibition of which could lessen the ability of normal, healthy cells to protect themselves from the cytotoxic agents.
SUMMARY OF THE INVENTION
In spite of the methodological possibilities for detecting expression of MDR1, the use of P-gp expression and functional tests to predict response to therapy has not been very successful. Specifically, while there have been indications of clinical utility for such a test, the results have not been sufficiently strong to warrant routine testing. What has been lacking is a statistical algorithm relating response potential to chemotherapy on a patient-specific basis with P-gp function to the modulatory effects of zosuquidar, the iinmunophenotype, and cytogenetics of the cancer cells, and clinical data such as patient age.
Zosuquidar selectively inhibits MDRl activity, allowing for the accumulation of sufficient chemotherapeutic agent to allow 'for effective therapy and tumor cell killing.
MDR1 may be present in the tumor cells at the time of diagnosis or it may be acquired during treatment or remission of the cancer. It is desirable to identify patients who would benefit most from zosuquidar therapy to target that patient population, i.e., MDRl-positive. A highly sensitive and reproducible diagnostic test for the functional expression of MDR1 is required to accomplish this goal.
Testing methodology is provided that improves the efficacy rates for any P-gp substrate in a patient population with demonstrated pump activation, resulting in enhanced cure rates, cancer free survival rates, and overall survival rates for oncolytic drugs.
Accordingly, in a first aspect a method of treating a cancer is provided, the method comprising the steps of determining P-glycoprotein expression or P-glycoprotein function in the cancer cells; selecting a treatment for the patient, based on the P-glycoprotein expression; and administering the treatment, whereby the cancer is treated.
In an embodiment of the first aspect, P-glycoprotein expression is determined by an antibody assay, and the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with,a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when positive P-glycoprotein expression is observed in at least about 10% of the cells tested in the antibody assay. Positive P-glycoprotein expression can be observed in from about 10% to about 25% of the cells tested in the antibody assay.
In an embodiment of the first aspect, P-glycoprotein expression is deterinined by an antibody assay, and the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when positive P-glycoprotein expression is observed for less than about 10% of the cells tested in the antibody assay.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when, in the P-glycoprotein dye accumulation assay, a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is at least about 1:1.2, e.g., from about 1:1.2 to about 1:1.5.
In an erribodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye accumulation assay, a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is less than about 1:1.2.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux wlien, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is at least about 1:1.2, e.g., from about 1:1.2 to about 1:1.5.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is at least about 30% higher than that contained in baseline control cells, and cells incubated in a presence of the P-glycoprotein efflux pump inhibitor can have dye levels at least about 30%
higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor. An amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor can be from about 30% to about 50% higher than that contained in baseline control cells, and cells incubated in a presence of the P-glycoprotein efflux pump inhibitor can have dye levels from about 30% to about 50% higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is less than about 1:1.2.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is less than about 30% higher than that contained in baseline control cells, and cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels less than about 30% higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
In an embodiment of the first aspect, the P-glycoprotein efflux pump inhibitor is selected from the group consisting of zosuquidar, Tariquidar, or Tesmilifene.
In an embodiment of the first aspect, the cancer is acute myelogenous leukemia.
In an embodiment of the first aspect, the cancer is a carcinoma, e.g., breast cancer or ovarian cancer.
In an embodiment of the first aspect, the cancer is a sarcoma.
In spite of the methodological possibilities for detecting expression of MDR1, the use of P-gp expression and functional tests to predict response to therapy has not been very successful. Specifically, while there have been indications of clinical utility for such a test, the results have not been sufficiently strong to warrant routine testing. What has been lacking is a statistical algorithm relating response potential to chemotherapy on a patient-specific basis with P-gp function to the modulatory effects of zosuquidar, the iinmunophenotype, and cytogenetics of the cancer cells, and clinical data such as patient age.
Zosuquidar selectively inhibits MDRl activity, allowing for the accumulation of sufficient chemotherapeutic agent to allow 'for effective therapy and tumor cell killing.
MDR1 may be present in the tumor cells at the time of diagnosis or it may be acquired during treatment or remission of the cancer. It is desirable to identify patients who would benefit most from zosuquidar therapy to target that patient population, i.e., MDRl-positive. A highly sensitive and reproducible diagnostic test for the functional expression of MDR1 is required to accomplish this goal.
Testing methodology is provided that improves the efficacy rates for any P-gp substrate in a patient population with demonstrated pump activation, resulting in enhanced cure rates, cancer free survival rates, and overall survival rates for oncolytic drugs.
Accordingly, in a first aspect a method of treating a cancer is provided, the method comprising the steps of determining P-glycoprotein expression or P-glycoprotein function in the cancer cells; selecting a treatment for the patient, based on the P-glycoprotein expression; and administering the treatment, whereby the cancer is treated.
In an embodiment of the first aspect, P-glycoprotein expression is determined by an antibody assay, and the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with,a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when positive P-glycoprotein expression is observed in at least about 10% of the cells tested in the antibody assay. Positive P-glycoprotein expression can be observed in from about 10% to about 25% of the cells tested in the antibody assay.
In an embodiment of the first aspect, P-glycoprotein expression is deterinined by an antibody assay, and the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when positive P-glycoprotein expression is observed for less than about 10% of the cells tested in the antibody assay.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when, in the P-glycoprotein dye accumulation assay, a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is at least about 1:1.2, e.g., from about 1:1.2 to about 1:1.5.
In an erribodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye accumulation assay, a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is less than about 1:1.2.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux wlien, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is at least about 1:1.2, e.g., from about 1:1.2 to about 1:1.5.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is at least about 30% higher than that contained in baseline control cells, and cells incubated in a presence of the P-glycoprotein efflux pump inhibitor can have dye levels at least about 30%
higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor. An amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor can be from about 30% to about 50% higher than that contained in baseline control cells, and cells incubated in a presence of the P-glycoprotein efflux pump inhibitor can have dye levels from about 30% to about 50% higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is less than about 1:1.2.
In an embodiment of the first aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is less than about 30% higher than that contained in baseline control cells, and cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels less than about 30% higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
In an embodiment of the first aspect, the P-glycoprotein efflux pump inhibitor is selected from the group consisting of zosuquidar, Tariquidar, or Tesmilifene.
In an embodiment of the first aspect, the cancer is acute myelogenous leukemia.
In an embodiment of the first aspect, the cancer is a carcinoma, e.g., breast cancer or ovarian cancer.
In an embodiment of the first aspect, the cancer is a sarcoma.
In an embodiment of the first aspect, the cancer is a hematologic malignancy, e.g., acute lymphoblastic leukemia, chronic myeloid leukemia, plasma cell dyscrasias, lymphoma, or myelodysplasia.
In an embodiment of the first aspect, the chemotherapeutic agent is an anthracycline, e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, or mitoxantrone.
In an embodiment of the first aspect, the chemotherapeutic agent is a Topoisomerase-II inhibitor, e.g., etoposide or teniposide.
In an embodiment of the first aspect, the chemotherapeutic agent is a vinca, e.g., vincristine, vinblastine, vinorelbine, or vindesine.
In an embodiment of the first aspect, the chemotherapeutic agent is a taxane, e.g., paclitaxel or docetaxel.
In an embodiment of the first aspect, the chemotherapeutic agent is selected from the group consisting of gleevec, dactinomycin, bisantrene, mitoxantrone, actinomyocin D, mithomycin C, mitramycin, methotrexate, adriamycin, mitomycin, mithramycin, anthracene, or epipodophyllo-toxin.
In a second aspect a pharmaceutical kit is provided, the kit comprising at least one dose of a P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene; directions for conducting a diagnostic for determining P -glycoprotein expression or P-glycoprotein function associated with the cancer; and directions for administering the P-glycoprotein efflux pump inhibitor and a chemotherapeutic agent that is a substrate for P-glycoprotein efflux to the patient to treat the cancer when P-glycoprotein expression or P-glycoprotein function is positive.
In a third aspect a method of treating a condition in a patient by administering a therapeutic agent that is a substrate for P-glycoprotein efflux is provided, the method comprising the steps of determining P-glycoprotein expression or P-glycoprotein function; and administering the therapeutic agent in combination with a P-glycoprotein efflux pump inhibitor when P-gp expression is positive.
In an embodiment of the third aspect, P-glycoprotein expression is determined by an antibody assay, and positive P-glycoprotein expression is observed in at least about 10%, e.g., from about 10% to about 25%, of the cells tested in the antibody assay.
In an embodiment of the third aspect, P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is at least about 1:1.2, e.g., from about 1:1.2 to about 1:1.5.
In an embodiment of the third aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is at least about 1:1.2, e.g., from about 1:1.2 to about 1:1.5.
In an embodiment of the third aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is at least about 30%
higher than that contained in baseline control cells, and cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels at least about 30% higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
In an embodiment of the third aspect, the P-glycoprotein efflux pump inhibitor is selected from the group consisting of zosuquidar, Tariquidar, or Tesmilifene.
In an embodiment of the third aspect, the therapeutic agent comprises an immunosuppressant, e.g., cyclosporine, cyclosporine A, or tacrolimus.
In an embodiment of the third aspect, the therapeutic agent comprises a steroid, e.g., dexamethasone, hydrocortisone, corticosterone, triamcinolone, aldosterone, or methylprednisolone.
In an embodiment of the third aspect, the therapeutic agent comprises an antiepileptic, e.g., phenytoin.
In an embodiment of the third aspect, the therapeutic agent comprises an antidepressant, e.g., citalopram, thioperidone, trazodone, trimipramine, amitriptyline, or phenothiazines.
In an embodiment of the third aspect, the therapeutic agent comprises an antipsychotic, e.g., fluphenazine, haloperidol, thioridazine, or trimipramine.
In an embodiment of the third aspect, the therapeutic agent comprises a protease inhibitor, e.g., amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir.
In an embodiment of the third aspect, the therapeutic agent comprises a calcium blocker, e.g., bepridil, diltiazem, flunarizine, lomerizine, secoverine, tamolarizine, verapamil, nicardipine, prenylamine, or fendiline.
In an embodiment of the third aspect, the therapeutic agent comprises a cardiac drug, e.g., digoxin, diltiazem, verapamil, or talinolol.
In a fourth aspect, a pharmaceutical kit is provided, the kit comprising at least one dose of a P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene; directions for conducting a diagnostic for determining a value for P-gp expression associated with a condition; and directions for administering the P-glycoprotein efflux pump inhibitor and a therapeutic agent that is a substrate for P-glycoprotein efflux to the patient to treat the condition when P-glycoprotein expression or P-glycoprotein function is pbsitive.
In a fifth aspect, a method of treating a cancer in a patient is provided, the method comprising the steps of conducting a P-glycoprotein efflux assay on the cancer cells in the presence of a P-glycoprotein efflux inhibitor, whereby a first value for P-glycoprotein function is obtained; conducting a P-glycoprotein efflux assay on the cancer cells in the absence of a P-glycoprotein efflux inhibitor, whereby a second value for P-glycoprotein function is obtained; comparing the first value and the second value for P-glycoprotein function, wherein the patient exhibits inhibitable P-glycoprotein efflux when the first value is greater than the second value; and administering to the patient exhibiting inhibitable P-glycoprotein efflux the P-glycoprotein efflux inhibitor and a chemotherapeutic agent that is a substrate for P-gp efflux.
In an embodiment of the fifth aspect, the patient exhibits inhibitable P-glycoprotein efflux when a ratio of the second value to the first value is greater than or equal to about 1:1.2.
In an embodiment of the fifth aspect, the patient exhibits inhibitable P-glycoprotein efflux when a ratio of the second value to the first value is from about 1:1.2 to about 1:1.5.
In an embQdiment of the fifth aspect, the patient exhibits inhibitable P-glycoprotein efflux when the first value is at least about 30% higher than the second value.
In an embodiment of the fifth aspect, the patient exhibits inhibitable P-glycoprotein efflux when the first value is from about 30% to about 50% higher than the second value.
In an embodiment of the fifth aspect, the P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene.
In an embodiment of the first aspect, the chemotherapeutic agent is an anthracycline, e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, or mitoxantrone.
In an embodiment of the first aspect, the chemotherapeutic agent is a Topoisomerase-II inhibitor, e.g., etoposide or teniposide.
In an embodiment of the first aspect, the chemotherapeutic agent is a vinca, e.g., vincristine, vinblastine, vinorelbine, or vindesine.
In an embodiment of the first aspect, the chemotherapeutic agent is a taxane, e.g., paclitaxel or docetaxel.
In an embodiment of the first aspect, the chemotherapeutic agent is selected from the group consisting of gleevec, dactinomycin, bisantrene, mitoxantrone, actinomyocin D, mithomycin C, mitramycin, methotrexate, adriamycin, mitomycin, mithramycin, anthracene, or epipodophyllo-toxin.
In a second aspect a pharmaceutical kit is provided, the kit comprising at least one dose of a P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene; directions for conducting a diagnostic for determining P -glycoprotein expression or P-glycoprotein function associated with the cancer; and directions for administering the P-glycoprotein efflux pump inhibitor and a chemotherapeutic agent that is a substrate for P-glycoprotein efflux to the patient to treat the cancer when P-glycoprotein expression or P-glycoprotein function is positive.
In a third aspect a method of treating a condition in a patient by administering a therapeutic agent that is a substrate for P-glycoprotein efflux is provided, the method comprising the steps of determining P-glycoprotein expression or P-glycoprotein function; and administering the therapeutic agent in combination with a P-glycoprotein efflux pump inhibitor when P-gp expression is positive.
In an embodiment of the third aspect, P-glycoprotein expression is determined by an antibody assay, and positive P-glycoprotein expression is observed in at least about 10%, e.g., from about 10% to about 25%, of the cells tested in the antibody assay.
In an embodiment of the third aspect, P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is at least about 1:1.2, e.g., from about 1:1.2 to about 1:1.5.
In an embodiment of the third aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is at least about 1:1.2, e.g., from about 1:1.2 to about 1:1.5.
In an embodiment of the third aspect, P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is at least about 30%
higher than that contained in baseline control cells, and cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels at least about 30% higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
In an embodiment of the third aspect, the P-glycoprotein efflux pump inhibitor is selected from the group consisting of zosuquidar, Tariquidar, or Tesmilifene.
In an embodiment of the third aspect, the therapeutic agent comprises an immunosuppressant, e.g., cyclosporine, cyclosporine A, or tacrolimus.
In an embodiment of the third aspect, the therapeutic agent comprises a steroid, e.g., dexamethasone, hydrocortisone, corticosterone, triamcinolone, aldosterone, or methylprednisolone.
In an embodiment of the third aspect, the therapeutic agent comprises an antiepileptic, e.g., phenytoin.
In an embodiment of the third aspect, the therapeutic agent comprises an antidepressant, e.g., citalopram, thioperidone, trazodone, trimipramine, amitriptyline, or phenothiazines.
In an embodiment of the third aspect, the therapeutic agent comprises an antipsychotic, e.g., fluphenazine, haloperidol, thioridazine, or trimipramine.
In an embodiment of the third aspect, the therapeutic agent comprises a protease inhibitor, e.g., amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir.
In an embodiment of the third aspect, the therapeutic agent comprises a calcium blocker, e.g., bepridil, diltiazem, flunarizine, lomerizine, secoverine, tamolarizine, verapamil, nicardipine, prenylamine, or fendiline.
In an embodiment of the third aspect, the therapeutic agent comprises a cardiac drug, e.g., digoxin, diltiazem, verapamil, or talinolol.
In a fourth aspect, a pharmaceutical kit is provided, the kit comprising at least one dose of a P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene; directions for conducting a diagnostic for determining a value for P-gp expression associated with a condition; and directions for administering the P-glycoprotein efflux pump inhibitor and a therapeutic agent that is a substrate for P-glycoprotein efflux to the patient to treat the condition when P-glycoprotein expression or P-glycoprotein function is pbsitive.
In a fifth aspect, a method of treating a cancer in a patient is provided, the method comprising the steps of conducting a P-glycoprotein efflux assay on the cancer cells in the presence of a P-glycoprotein efflux inhibitor, whereby a first value for P-glycoprotein function is obtained; conducting a P-glycoprotein efflux assay on the cancer cells in the absence of a P-glycoprotein efflux inhibitor, whereby a second value for P-glycoprotein function is obtained; comparing the first value and the second value for P-glycoprotein function, wherein the patient exhibits inhibitable P-glycoprotein efflux when the first value is greater than the second value; and administering to the patient exhibiting inhibitable P-glycoprotein efflux the P-glycoprotein efflux inhibitor and a chemotherapeutic agent that is a substrate for P-gp efflux.
In an embodiment of the fifth aspect, the patient exhibits inhibitable P-glycoprotein efflux when a ratio of the second value to the first value is greater than or equal to about 1:1.2.
In an embodiment of the fifth aspect, the patient exhibits inhibitable P-glycoprotein efflux when a ratio of the second value to the first value is from about 1:1.2 to about 1:1.5.
In an embQdiment of the fifth aspect, the patient exhibits inhibitable P-glycoprotein efflux when the first value is at least about 30% higher than the second value.
In an embodiment of the fifth aspect, the patient exhibits inhibitable P-glycoprotein efflux when the first value is from about 30% to about 50% higher than the second value.
In an embodiment of the fifth aspect, the P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene.
In an embodiment of the fifth aspect, the step of determining a value for P-gp expression comprises conducting an assay, wherein the assay is selected based on the cancer.
In an embodiment of the fifth aspect, the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression comprises conducting a flow cytometry assay.
In an embodiment of the fifth aspect, the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression coinprises conducting a radiolabeled drug assay.
In an embodiment of the fifth aspect, the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression comprises.conducting a solid phase immunoassay that measure a cell-associated drug with an anti-drug antibody.
In an embodiment of the fifth aspect, the cancer is a solid tumor, and wherein the step of determining a value for P-gp expression comprises conducting an immunocytochemistry assay.
In an embodiment of the fifth aspect, the cancer is a solid tumor, and wherein the step of determining a value for P-gp expression comprises conducting an immunohistochemistry assay.
In an embodiment of the fifth aspect, the assay quantifies P-gp function.
In an embodiment of the fifth aspect, the cancer is acute myelogenous leukemia.
In an embodiment of the fifth aspect, the cancer is a carcinoma, e.g., breast cancer or ovarian cancer.
In an embodiment of the fifth aspect, the cancer is a sarcoma.
In an embodiment of the fifth aspect, the cancer is a hematologic malignancy, e.g., acute lymphoblastic leukemia, chronic myeloid leukemia, plasma cell dyscrasias, lymphoma, or myelodysplasia.
In an embodiment of the fifth aspect, the chemotherapeutic agent is an anthracycline, e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, or mitoxantrone.
In an embodiment of the fifth aspect, the chemotherapeutic agent is a Topoisomerase-II inhibitor, e.g., etoposide or teniposide.
In an embodiment of the fifth aspect, the chemotherapeutic agent is a vinca, e.g., vincristine, vinblastine, vinorelbine, or vindesine.
In an embodiment of the fifth aspect, the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression comprises conducting a flow cytometry assay.
In an embodiment of the fifth aspect, the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression coinprises conducting a radiolabeled drug assay.
In an embodiment of the fifth aspect, the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression comprises.conducting a solid phase immunoassay that measure a cell-associated drug with an anti-drug antibody.
In an embodiment of the fifth aspect, the cancer is a solid tumor, and wherein the step of determining a value for P-gp expression comprises conducting an immunocytochemistry assay.
In an embodiment of the fifth aspect, the cancer is a solid tumor, and wherein the step of determining a value for P-gp expression comprises conducting an immunohistochemistry assay.
In an embodiment of the fifth aspect, the assay quantifies P-gp function.
In an embodiment of the fifth aspect, the cancer is acute myelogenous leukemia.
In an embodiment of the fifth aspect, the cancer is a carcinoma, e.g., breast cancer or ovarian cancer.
In an embodiment of the fifth aspect, the cancer is a sarcoma.
In an embodiment of the fifth aspect, the cancer is a hematologic malignancy, e.g., acute lymphoblastic leukemia, chronic myeloid leukemia, plasma cell dyscrasias, lymphoma, or myelodysplasia.
In an embodiment of the fifth aspect, the chemotherapeutic agent is an anthracycline, e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, or mitoxantrone.
In an embodiment of the fifth aspect, the chemotherapeutic agent is a Topoisomerase-II inhibitor, e.g., etoposide or teniposide.
In an embodiment of the fifth aspect, the chemotherapeutic agent is a vinca, e.g., vincristine, vinblastine, vinorelbine, or vindesine.
In an embodiment of the fifth aspect, the chemotherapeutic agent is a taxane, e.g., paclitaxel or docetaxel.
In an embodiment of the fifth aspect, the chemotherapeutic agent is selected from the group consisting of Gleevec, dactinomycin, mitomycin, mithramycin, and Mylotarg.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 presents typical histograms of K562/R7 cells cultured in the absence of DiOC2, in the absence of zosuquidar, and in the presence of zosuquidar.
Figure 2 provides a comparison between accumulation and efflux assays with leukemia cells.
Figure 3 provides a coinparison of efflux and accumulation assay data for leukemia cells in the absence or presence of zosuquidar.
Figure 4 presents the efflux characteristics of K562/R7 cells loaded with 40 ng/ml DiOC2 in the presence of 200 ng/ml zosuquidar for 60 minutes.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The following description and examples illustrate a preferred embodiment of the present invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope.
Accordingly, the description of a preferred embodiment should not be deemed to limit the scope of the present invention.
Cancer Targets Many forms of cancer express P-gp, and thus can benefit from the administration of a P-gp efflux pump inhibitor when treated with a chemotherapeutic agent that is a substrate for P-gp efflux. For example, most solid tumors, lymphomas, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, myeloma, and sarcoma are all cancers with a P-gp expression of greater than 50%. Lymphocytic leukemia also has a P-gp expression of greater than 50%. The P-gp expression of breast cancers is about 30%. For metastatic breast cancer, 63% express P-gp. The methods and formulations of preferred embodiments are particularly efficacious in the treatment of any malignancy exhibiting some degree of P-gp expression and/or function, or in patients who are P-gp positive.
One form of cancer characterized by high rates of P-gp expression is acute myelogenous leukemia. There are approximately 11,000 new cases of AML per year in the United States and 9,000 new cases in the five major EU countries. In addition, the World Health Organization defines advanced myelodysplastic syndrome (MDS) as AML.
In an embodiment of the fifth aspect, the chemotherapeutic agent is selected from the group consisting of Gleevec, dactinomycin, mitomycin, mithramycin, and Mylotarg.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 presents typical histograms of K562/R7 cells cultured in the absence of DiOC2, in the absence of zosuquidar, and in the presence of zosuquidar.
Figure 2 provides a comparison between accumulation and efflux assays with leukemia cells.
Figure 3 provides a coinparison of efflux and accumulation assay data for leukemia cells in the absence or presence of zosuquidar.
Figure 4 presents the efflux characteristics of K562/R7 cells loaded with 40 ng/ml DiOC2 in the presence of 200 ng/ml zosuquidar for 60 minutes.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The following description and examples illustrate a preferred embodiment of the present invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope.
Accordingly, the description of a preferred embodiment should not be deemed to limit the scope of the present invention.
Cancer Targets Many forms of cancer express P-gp, and thus can benefit from the administration of a P-gp efflux pump inhibitor when treated with a chemotherapeutic agent that is a substrate for P-gp efflux. For example, most solid tumors, lymphomas, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, myeloma, and sarcoma are all cancers with a P-gp expression of greater than 50%. Lymphocytic leukemia also has a P-gp expression of greater than 50%. The P-gp expression of breast cancers is about 30%. For metastatic breast cancer, 63% express P-gp. The methods and formulations of preferred embodiments are particularly efficacious in the treatment of any malignancy exhibiting some degree of P-gp expression and/or function, or in patients who are P-gp positive.
One form of cancer characterized by high rates of P-gp expression is acute myelogenous leukemia. There are approximately 11,000 new cases of AML per year in the United States and 9,000 new cases in the five major EU countries. In addition, the World Health Organization defines advanced myelodysplastic syndrome (MDS) as AML.
There are approximately 4,000 cases of advanced MDS in the US and 3,000 cases in the five major EU countries. As a result, the target patient population for zosuquidar is approximately 15,000 patients in the U.S. and 12,000 in the major European markets.
Adult AML presents greater treatment challenges when compared to pediatric AML (age < 15 years). Due in part to a more resilient patient population and a more sensitive disease, the 5 year survival rates for pediatric AML is 50% (late 1990s). In contrast, due in part to multiple co-morbid conditions and a more resistant disease, the 5 year survival rates for adult AML are only 13% (late 1990s). The 5 year survival rate for patients over 65 is only 7%.
Standard induction therapy in the U.S. for newly diagnosed AML patients is cytarabine with either idarubicin or daunorubicin (both P-gp substrates). In one study, 71% of AML patients greater than 60 years of age expressed moderate to high levels of P-gp. The expression was associated with a reduction in the complete remission (CR) rate.
The CR rate for P-gp negative AML patients was 67% compared to 34% for P-gp positive patients. This combination of high levels of P-gp expression with the nearly universal use of drugs that are P-gp substrates provides a ready opportunity for the coadministration of a P-gp inhibitor in patients with AML.
Approximately 75% of AML patients are over age 60, and 71% are P-gp positive.
The expression was associated with a reduction in the complete remission (CR) rate. The CR rate for P-gp negative AML patients was 67% compared to 34% for P-gp positive patients. Clinical outcomes in terms of patient survival rates are significantly better for patients that are P-gp negative than for those that are P-gp positive - a 50%
survival rate at approximately 3-4 months for P-gp positive patients, versus a 50% survival rate at approximately 15 months for P-gp negative patients. See Campos, et al., Blood, 79:473-476, 1992.
Approximately 75% of AML patients will eventually relapse and be candidates for additional treatment. Relapsed AML. patients typically require prolonged hospitalization, and their prognosis is generally poor. Of these relapsed patients, approximately 80% are P-gp positive.
Over 129,000 metastatic breast cancer patients are treated with chemotherapy in the United States and Europe annually. Of these patients, over 81,000 are treated with a P-gp substrate. 41% of breast cancers express P-gp. For metastatic breast cancer, 63%
express P-gp.
Adult AML presents greater treatment challenges when compared to pediatric AML (age < 15 years). Due in part to a more resilient patient population and a more sensitive disease, the 5 year survival rates for pediatric AML is 50% (late 1990s). In contrast, due in part to multiple co-morbid conditions and a more resistant disease, the 5 year survival rates for adult AML are only 13% (late 1990s). The 5 year survival rate for patients over 65 is only 7%.
Standard induction therapy in the U.S. for newly diagnosed AML patients is cytarabine with either idarubicin or daunorubicin (both P-gp substrates). In one study, 71% of AML patients greater than 60 years of age expressed moderate to high levels of P-gp. The expression was associated with a reduction in the complete remission (CR) rate.
The CR rate for P-gp negative AML patients was 67% compared to 34% for P-gp positive patients. This combination of high levels of P-gp expression with the nearly universal use of drugs that are P-gp substrates provides a ready opportunity for the coadministration of a P-gp inhibitor in patients with AML.
Approximately 75% of AML patients are over age 60, and 71% are P-gp positive.
The expression was associated with a reduction in the complete remission (CR) rate. The CR rate for P-gp negative AML patients was 67% compared to 34% for P-gp positive patients. Clinical outcomes in terms of patient survival rates are significantly better for patients that are P-gp negative than for those that are P-gp positive - a 50%
survival rate at approximately 3-4 months for P-gp positive patients, versus a 50% survival rate at approximately 15 months for P-gp negative patients. See Campos, et al., Blood, 79:473-476, 1992.
Approximately 75% of AML patients will eventually relapse and be candidates for additional treatment. Relapsed AML. patients typically require prolonged hospitalization, and their prognosis is generally poor. Of these relapsed patients, approximately 80% are P-gp positive.
Over 129,000 metastatic breast cancer patients are treated with chemotherapy in the United States and Europe annually. Of these patients, over 81,000 are treated with a P-gp substrate. 41% of breast cancers express P-gp. For metastatic breast cancer, 63%
express P-gp.
Zosuquidar U.S. Pat. Nos. 5,643,909 and 5,654,304 disclose a series of 10,11-methanobenzosuberane derivatives useful in enliancing the efficacy of existing cancer chemotherapeutics and for treating multidrug resistance. One such derivative having good activity, oral bioavailability, and stability, is zosuquidar, a compound of formula (2R)-anti-5-3 -[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2-hydroxypropoxy } quinoline.
HO N
H~
F
~~~l"IIN N H O
H~
Zosuquidar Given the limitations of previous generations of MDR modulators, three preclinical critical success factors were identified and met for zosuquidar:
1) it is a potent inhibitor of P-glycoprotein; 2) it is selective for P-glycoprotein; and 3) no pharmacokinetic interaction with co-administered chemotherapy is observed.
Zosuquidar is extremely potent in vitro (Ki = 59 nM) and is among the most active modulators of P-gp-associated resistance described to date. Zosuquidar has also demonstrated good in vivo activity in preclinical animal studies. In addition, the compound does not appear to be a substrate for P-gp efflux, resulting in a relatively long duration of reversal activity in resistant cells even after the modulator has been withdrawn.
Another significant attribute of zosuquidar as an MDR modulator is the minimal pharmacokinetic (PK) interactions with several oncolytics tested in preclinical models.
Such minimal PK interaction permits normal doses of oncolytics to be administered and also a more straightforward interpretation of the clinical results.
HO N
H~
F
~~~l"IIN N H O
H~
Zosuquidar Given the limitations of previous generations of MDR modulators, three preclinical critical success factors were identified and met for zosuquidar:
1) it is a potent inhibitor of P-glycoprotein; 2) it is selective for P-glycoprotein; and 3) no pharmacokinetic interaction with co-administered chemotherapy is observed.
Zosuquidar is extremely potent in vitro (Ki = 59 nM) and is among the most active modulators of P-gp-associated resistance described to date. Zosuquidar has also demonstrated good in vivo activity in preclinical animal studies. In addition, the compound does not appear to be a substrate for P-gp efflux, resulting in a relatively long duration of reversal activity in resistant cells even after the modulator has been withdrawn.
Another significant attribute of zosuquidar as an MDR modulator is the minimal pharmacokinetic (PK) interactions with several oncolytics tested in preclinical models.
Such minimal PK interaction permits normal doses of oncolytics to be administered and also a more straightforward interpretation of the clinical results.
Assays for Multidrug, Resistance There are a variety of techniques to detect expression of MDR1. The detection and quantitation of MDR1 protein is typically achieve using immunological techniques.
For hematopoietic cells such as those from leukemia or lymphoma patients, the techniques include flow cytometry and fixed cells on microscope slides. The cells are treated with antibodies specific for the MDR1 protein, such as the mouse ARK-monoclonal antibody. Such antibodies can be directly labeled with fluorescent probe, or detected using subsequent reagents such as goat anti-mouse IgG-FITC. Flow cytometry allows for direct quantitative determinations of the full spectrum of MDR1 expression using channel number or fluorescence intensity. Microscopic examination of the slide preparations can give qualitative results (-, +, ++, and the like) or, in conjunction with an image analyzer, quantitative evaluations typically expressed in pixels.
For solid tumors, such as breast cancer, typically immunocytochemistry (ICC) or immunohistochemistry (IHC) techniques are employed. Using, for example, frozen sections or paraffin blocks, the detection techniques are the same as described for fixed leukemia cells on microscope slides. Expression of MDR1 can also be achieved with the measurement of specific mRNA levels. Cell slides can be processed, and levels of mRNA discerned using basic molecular biology techniques such as quantitative fluorescent PCR. Alternatively, the cells of interest can be lysed, processed, and following PCR of the mRNA, the product can be detected and quantitated following gel electrophoresis. Anti-sense targeting of MDR1 mRNA is also possible, followed by standard techniques for quantitative determinations. Radio-labeled probes followed by autoradiography or other radiodetection techniques can also be used to get a relative estimate of MDR1 protein or mRNA expression. Thus, there exists a broad range of methods for the detection and quantitation of the spectrum of MDR1 expression exhibited by a patient population.
The relative expression of MDR1 is possible in vivo. MDR1-specific antibodies labeled with any number of detectable markers, such as radioactive compounds detectable with positron emission tomography (PET), single-photon emission computed tomography (SPECT) or compounds detectable with magnetic resonance imaging (MRI) can be used to assess MDR1 expression in patients with cancer.
Of equal importance to MDRl protein and mRNA expression is the quantitation of MDR1 function, i.e., functional expression. MDR1 functions as a cytoplasmic membrane pump, effluxing compounds such as drugs and toxins from the cytoplasm to the exterior of the cell. Compounds acted on by MDR1 are termed MDR1 substrates:
Detection of MDR1 function therefore involves detection of substrate efflux, such as drugs or, alternatively, detecting efflux of surrogate fluorescent dye markers as DiOC2 (3,3'-diethyloxacarbocyanine iodide) or Rhodamine 123 (Rh123, or 2-(6-amino-3-imino-3H-xanthen-9-yl)benzoic acid, methyl ester). For single cell suspensions, such as blood or bone marrow from leukemia patients, the cells are exposed in tissue culture to a substrate for MDR1, such as the aforementioned dye markers, radiolabeled drugs, or drugs that can be quantitated by other means such as fluorescence. At physiological temperature (37 C) the net accumulation of the substrate over time, in the presence or absence of specific MDRl inhibitors, gives an indication of the MDRl functional activity exhibited by the cells. Alternatively, the single cell suspension can be exposed to the substrate, i.e., loaded with, and subsequent efflux of the substrate over time monitored at physiological teinperature in the presence or absence of specific MDR1 inhibitors.
PET, SPECT, and MRI techniques can also be used to assess MDR1 function in cancer patients. Thus, small organic chemicals as well as metal complexes which serve as MDR1 substrates can be rendered as radionuclides or other markers which are detectable by the imaging technologies. Additionally, functional expression in solid tumors can be more efficiently ascertained by ICC/IHC techniques with prior labeling of the tumor cells while in the patient.
Diagnostic Testing for P-gp Expression and Efflux Pump Activity Diagnostic testing methods for P-gp expression and efflux pump activity can be used to prospectively stratify patients for treatment optimization in treating malignancies exhibiting P-gp expression or function, such as acute myelogenous leukemia, most solid tumors, lymphomas, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, myeloma, lymphocytic leukemia, and sarcoma.
In a particularly preferred embodiment, susceptibility of the individual patient's cancer and natural kill (NK) cells to the inhibitory effects of zosuquidar on that patient's P-gp expression and function is incorporated into the treatment regimen. Thus, the cells of interest are assessed as in one of the above-described methods both before and after exposure to zosuquidar. Such an assay can be considered a "zosuquidar drugability"
assay to determine the potential for improved response to chemotherapy with administration of zosuquidar. Similar methodology can be employed in providing assays to determine drugability for other P-gp efflux inhibitors, and thus determine the potential for improved response to chemotherapy treatment regimens employing P-gp efflux inhibitors.
Ranges of P-gp efflux pump activation and populations of cells have been correlated to identify and stratify patients for future treatment with enhanced clinical outcomes. The diagnostic testing employed preferably includes assay methods as described above, including immunophenotyping and cytogenetics of the cancer cells, as well as a diagnostic algorithm to relate the phenotypic and clinical data to chemotherapeutic response potential.
While the techniques are especially preferred for use in administering zosuquidar, the techniques are applicable to any therapeutic drug that is a substrate for P-gp efflux.
Such drugs include, but are not limited to, P-glycoprotein substrates;
anticancer drugs (e.g., vinca alkaloids such as vinblastine and vincristine; anthracyclines such as doxorubicin, daunorubicin, epirubicin; anthracenes such as bisantrene and mitoxantrone;
epipodophyllo-toxins such as etoposide and teniposide; and other anticancer drugs such as actinomyocin D, mithomycin C, mitramycin, methotrexate, docetaxel, etoposide (VP- 16), paclitaxel, docetaxel, and adriamycin); immunosuppressants (e.g., cyclosporine A, tacrolimus); steroids (e.g., dexamethasone, hydrocortisone, corticosterone, triamcinolone, aldosterone, methylprednisolone); antiepileptics (e.g., phenytoin);
antidepressants (e.g., citalopram, thioperidone, trazodone, trimipramine, ainitriptyline, phenothiazines);
antipsychotics (fluphenazine, haloperidol, thioridazine, trimipramine); HIV
protease inhibitors (e.g., amprenavir, indinavir, lopinavir, nelfinavir, ritqnavir, saquinavir); calcium blockers (e.g., bepridil, diltiazem, flunarizine, lomerizine, secoverine, tamolarizine, verapamil, nicardipine, prenylamine, fendiline); and cardiac drugs (e.g., digoxin, diltiazem, verapamil, talinolol).
A P-gp diagnostic test exhibits clinical utility for a broad range of disease states.
As discussed above, the drugs which are substrates of P-gp are quite varied as are the associated disease states. The use of a P-gp diagnostic test is best exemplified in the treatment of AML, where it has been demonstrated that the levels of P-gp expression and function are significantly related to response to the chemotherapy.
Preferred embodiments involve assessment on a patient-specific basis for zosuquidar to modulate P-gp function in the cancer cell population. Thus, the expression and function of P-gp is assessed in the absence and presence of zosuquidar with the patient's cancer and NK cells. A statistical algorithm to relate immunophenotype of the cancer cells, P-gp function and expression, cytogenetics, and certain clinical variables such as age to response potential to chemotherapy is used. This methodology can be applied to any form of cancer as related to chemotherapeutic agents which are substrates of P-gp as listed above.
The distribution of P-gp expression also has utility for a P-gp diagnostic beyond the oncology field. Affected organs can include the intestine, liver, placenta, kidneys, and blood brain barrier (BBB). The system of P-gp expression is believed to have evolved to eliminate or exclude toxins and metabolites. For unknown reasons, hematopoietic and lymphoid cells, such as myeloid, NK, and CD8 (cytotoxic T cells, CTL) cells also express P-gp. Disease states originating from these organs/cells can exhibit varied responses to therapy depending on the levels of P-gp expression. Moreover, P-gp is highly expressed by mucosal and luminal surfaces of organs which are involved in drug absorption, distribution, and excretion. Varied expression of P-gp can influence therapy by influencing drug pharmacokinetics in addition to pharmacodynamics. Therefore, a P-gp diagnostic test capable of stratifying patient populations according to therapeutic response potential has substantial clinical utility for a variety of disease conditions.
For example, treatment of autoimmune, other inflammatory diseases, and organ transplant with iminunosuppressive drugs, as well as with steroids, can be optimized using a P-gp diagnostic test. This is indicated by the enhanced expression of MDR1 in renal transplant patients who undergo graft rejection on cyclosporine. Other exainples include patients with rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. Varied expression of P-gp by the BBB can predict response to epilepsy drugs and other drugs used to treat mental disorders. Response potential to treatment of HIV and other viral therapeutics can also be optimized with a P-gp diagnostic test. Such a test can also find clinical utility in the prediction of adverse events, especially as related to the use of cardiovascular drugs. Such a test is not currently being conducted to predict prospectively response to therapy for this diverse disease set.
The identification of tumor cells expressing P-gp or exhibiting positive P-gp function involves a relationship between negative and positive control situations.
Expression assays that use antibodies to detect P-gp expression include controls of cells either not treated with primary antibody, or cells treated with an antibody of the same isotype as that of the anti-P-gp reagent. At a cutoff where cells treated under these latter conditions exhibited minimal positive reaction, e.g., 0-5% positive cells, positive results using the anti-P-gp antibody include 10% or more positive cells, typically 10-25%
positive cells. Functional assays involve a ratio of P-gp dye accumulation or efflux in the presence and absence of a specific P-gp inhibitor such as zosuquidar. For the accumulation assay format the amount of dye taken up by the cells in the presence of zosuquidar is divided by that amount of dye taken up by cells cultured without zosuquidar. For the efflux assay format the amount of dye eliminated from the cells in the presence of zosuquidar is divided by that amount of dye eliminated without zosuquidar in the culture. Positive P-gp functional activity is inferred for ratios greater than about 1:1.2, typically ratios of from about 1:1.2 to about 1:1.5. For the efflux P-gp functional assay, ratios can be used, as well as % efflux and % inhibition of efflux by zosuquidar or other P-gp modulators. Positive P-gp functional activity is inferred by % efflux of from about 30% to about 50%, and specific inhibition by a P-gp modulator is similarly from about 30% to about 50%.
Chemotherapeutic Regimens Utilizing Zosuquidar and Mylotar~
In preferred embodiments, a P-gp expression or efflux pump activity diagnostic is conducted to provide information in treating AML patients or patients with metastatic breast cancer with zosuquidar in combination with Mylotarg. If the results of the P-gp expression or efflux pump activity diagnostic indicates positive P-gp expression or efflux pump activity, then treatment with zosuquidar (or another P-gp efflux inhibitor) in combination with Mylotarg is initiated. If the results of the P-gp expression or efflux pump activity diagnostic indicate negative P-gp expression or efflux pump activity, then zosuquidar is expected not to yield an improvement in clinical outcome and another treatment option not involving administration of a P-gp efflux inhibitor is selected. In relapsed AML patients, it is generally considered acceptable clinical practice to wait for P-gp expression or efflux pump activity test results before initiating a treatment.
However, in certain embodiments it can be desirable to initiate treatment before receiving test results, and then reevaluate the desirability of continuing treatment, depending upon the test results. Most preferably, P-gp expression or efflux pump activity of a sample both in the presence and absence of the P-gp efflux inhibitor is compared, whereby the P-gp efflux that is inhibitable by the P-gp efflux inhibitor can be determined.
However, in certain embodiments wherein P-gp expression or function status correlates with expectation of clinical success, it can be useful to determine P-gp expression or efflux pump activity at any point in time.
Mylotarg was approved in May 2000 for relapsed CD33-positive AML patients over the age of 60. Mylotarg from Wyeth and Celltech is based on antibody-targeted chemotherapy. Mylotarg's highly specific antibody recognizes a cell-surface molecule, CD33, which is abundant on AML cells (>90%) but absent from norinal blood stem cells, the seeds from which normal blood and immune cells originate. The antibody is linked to calicheamicin, a potent chemotherapy agent. The antibody selectively targets leukemic blast cells and delivers calicheamicin to them. The chemical structure of Mylotarg is provided below.
n, average loading of hP67.6 callicheamicln derivative on antibody, is 2 to 3 moleslmole NtJ
NHNA'A hif~=~ C7 G~#;~
~~~ O CH3 O NH .f, O
0 OCM3 ON HN C3~
~O H
OCH3 CH2Cll x Ft+~a O a {~
~}"~3 v("'SIr1 CH3 1 OCH, 0 n There is a growing body of evidence to suggest that the calicheamicin component of Mylotarg is also an MDR substrate and subject to the P-gp efflux pump. In several studies, the cytotoxic effect of Mylotarg has been shown to be inversely correlated with the amount of P-gp present. Two MDR modulators, valspodar and the quinolone derivative MS-209, have both been shown to reverse the resistance to Mylotarg in P-gp expressing CD33(+) leukemia cells and clinical studies are underway in combination with cyclosporine.
For hematopoietic cells such as those from leukemia or lymphoma patients, the techniques include flow cytometry and fixed cells on microscope slides. The cells are treated with antibodies specific for the MDR1 protein, such as the mouse ARK-monoclonal antibody. Such antibodies can be directly labeled with fluorescent probe, or detected using subsequent reagents such as goat anti-mouse IgG-FITC. Flow cytometry allows for direct quantitative determinations of the full spectrum of MDR1 expression using channel number or fluorescence intensity. Microscopic examination of the slide preparations can give qualitative results (-, +, ++, and the like) or, in conjunction with an image analyzer, quantitative evaluations typically expressed in pixels.
For solid tumors, such as breast cancer, typically immunocytochemistry (ICC) or immunohistochemistry (IHC) techniques are employed. Using, for example, frozen sections or paraffin blocks, the detection techniques are the same as described for fixed leukemia cells on microscope slides. Expression of MDR1 can also be achieved with the measurement of specific mRNA levels. Cell slides can be processed, and levels of mRNA discerned using basic molecular biology techniques such as quantitative fluorescent PCR. Alternatively, the cells of interest can be lysed, processed, and following PCR of the mRNA, the product can be detected and quantitated following gel electrophoresis. Anti-sense targeting of MDR1 mRNA is also possible, followed by standard techniques for quantitative determinations. Radio-labeled probes followed by autoradiography or other radiodetection techniques can also be used to get a relative estimate of MDR1 protein or mRNA expression. Thus, there exists a broad range of methods for the detection and quantitation of the spectrum of MDR1 expression exhibited by a patient population.
The relative expression of MDR1 is possible in vivo. MDR1-specific antibodies labeled with any number of detectable markers, such as radioactive compounds detectable with positron emission tomography (PET), single-photon emission computed tomography (SPECT) or compounds detectable with magnetic resonance imaging (MRI) can be used to assess MDR1 expression in patients with cancer.
Of equal importance to MDRl protein and mRNA expression is the quantitation of MDR1 function, i.e., functional expression. MDR1 functions as a cytoplasmic membrane pump, effluxing compounds such as drugs and toxins from the cytoplasm to the exterior of the cell. Compounds acted on by MDR1 are termed MDR1 substrates:
Detection of MDR1 function therefore involves detection of substrate efflux, such as drugs or, alternatively, detecting efflux of surrogate fluorescent dye markers as DiOC2 (3,3'-diethyloxacarbocyanine iodide) or Rhodamine 123 (Rh123, or 2-(6-amino-3-imino-3H-xanthen-9-yl)benzoic acid, methyl ester). For single cell suspensions, such as blood or bone marrow from leukemia patients, the cells are exposed in tissue culture to a substrate for MDR1, such as the aforementioned dye markers, radiolabeled drugs, or drugs that can be quantitated by other means such as fluorescence. At physiological temperature (37 C) the net accumulation of the substrate over time, in the presence or absence of specific MDRl inhibitors, gives an indication of the MDRl functional activity exhibited by the cells. Alternatively, the single cell suspension can be exposed to the substrate, i.e., loaded with, and subsequent efflux of the substrate over time monitored at physiological teinperature in the presence or absence of specific MDR1 inhibitors.
PET, SPECT, and MRI techniques can also be used to assess MDR1 function in cancer patients. Thus, small organic chemicals as well as metal complexes which serve as MDR1 substrates can be rendered as radionuclides or other markers which are detectable by the imaging technologies. Additionally, functional expression in solid tumors can be more efficiently ascertained by ICC/IHC techniques with prior labeling of the tumor cells while in the patient.
Diagnostic Testing for P-gp Expression and Efflux Pump Activity Diagnostic testing methods for P-gp expression and efflux pump activity can be used to prospectively stratify patients for treatment optimization in treating malignancies exhibiting P-gp expression or function, such as acute myelogenous leukemia, most solid tumors, lymphomas, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, myeloma, lymphocytic leukemia, and sarcoma.
In a particularly preferred embodiment, susceptibility of the individual patient's cancer and natural kill (NK) cells to the inhibitory effects of zosuquidar on that patient's P-gp expression and function is incorporated into the treatment regimen. Thus, the cells of interest are assessed as in one of the above-described methods both before and after exposure to zosuquidar. Such an assay can be considered a "zosuquidar drugability"
assay to determine the potential for improved response to chemotherapy with administration of zosuquidar. Similar methodology can be employed in providing assays to determine drugability for other P-gp efflux inhibitors, and thus determine the potential for improved response to chemotherapy treatment regimens employing P-gp efflux inhibitors.
Ranges of P-gp efflux pump activation and populations of cells have been correlated to identify and stratify patients for future treatment with enhanced clinical outcomes. The diagnostic testing employed preferably includes assay methods as described above, including immunophenotyping and cytogenetics of the cancer cells, as well as a diagnostic algorithm to relate the phenotypic and clinical data to chemotherapeutic response potential.
While the techniques are especially preferred for use in administering zosuquidar, the techniques are applicable to any therapeutic drug that is a substrate for P-gp efflux.
Such drugs include, but are not limited to, P-glycoprotein substrates;
anticancer drugs (e.g., vinca alkaloids such as vinblastine and vincristine; anthracyclines such as doxorubicin, daunorubicin, epirubicin; anthracenes such as bisantrene and mitoxantrone;
epipodophyllo-toxins such as etoposide and teniposide; and other anticancer drugs such as actinomyocin D, mithomycin C, mitramycin, methotrexate, docetaxel, etoposide (VP- 16), paclitaxel, docetaxel, and adriamycin); immunosuppressants (e.g., cyclosporine A, tacrolimus); steroids (e.g., dexamethasone, hydrocortisone, corticosterone, triamcinolone, aldosterone, methylprednisolone); antiepileptics (e.g., phenytoin);
antidepressants (e.g., citalopram, thioperidone, trazodone, trimipramine, ainitriptyline, phenothiazines);
antipsychotics (fluphenazine, haloperidol, thioridazine, trimipramine); HIV
protease inhibitors (e.g., amprenavir, indinavir, lopinavir, nelfinavir, ritqnavir, saquinavir); calcium blockers (e.g., bepridil, diltiazem, flunarizine, lomerizine, secoverine, tamolarizine, verapamil, nicardipine, prenylamine, fendiline); and cardiac drugs (e.g., digoxin, diltiazem, verapamil, talinolol).
A P-gp diagnostic test exhibits clinical utility for a broad range of disease states.
As discussed above, the drugs which are substrates of P-gp are quite varied as are the associated disease states. The use of a P-gp diagnostic test is best exemplified in the treatment of AML, where it has been demonstrated that the levels of P-gp expression and function are significantly related to response to the chemotherapy.
Preferred embodiments involve assessment on a patient-specific basis for zosuquidar to modulate P-gp function in the cancer cell population. Thus, the expression and function of P-gp is assessed in the absence and presence of zosuquidar with the patient's cancer and NK cells. A statistical algorithm to relate immunophenotype of the cancer cells, P-gp function and expression, cytogenetics, and certain clinical variables such as age to response potential to chemotherapy is used. This methodology can be applied to any form of cancer as related to chemotherapeutic agents which are substrates of P-gp as listed above.
The distribution of P-gp expression also has utility for a P-gp diagnostic beyond the oncology field. Affected organs can include the intestine, liver, placenta, kidneys, and blood brain barrier (BBB). The system of P-gp expression is believed to have evolved to eliminate or exclude toxins and metabolites. For unknown reasons, hematopoietic and lymphoid cells, such as myeloid, NK, and CD8 (cytotoxic T cells, CTL) cells also express P-gp. Disease states originating from these organs/cells can exhibit varied responses to therapy depending on the levels of P-gp expression. Moreover, P-gp is highly expressed by mucosal and luminal surfaces of organs which are involved in drug absorption, distribution, and excretion. Varied expression of P-gp can influence therapy by influencing drug pharmacokinetics in addition to pharmacodynamics. Therefore, a P-gp diagnostic test capable of stratifying patient populations according to therapeutic response potential has substantial clinical utility for a variety of disease conditions.
For example, treatment of autoimmune, other inflammatory diseases, and organ transplant with iminunosuppressive drugs, as well as with steroids, can be optimized using a P-gp diagnostic test. This is indicated by the enhanced expression of MDR1 in renal transplant patients who undergo graft rejection on cyclosporine. Other exainples include patients with rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. Varied expression of P-gp by the BBB can predict response to epilepsy drugs and other drugs used to treat mental disorders. Response potential to treatment of HIV and other viral therapeutics can also be optimized with a P-gp diagnostic test. Such a test can also find clinical utility in the prediction of adverse events, especially as related to the use of cardiovascular drugs. Such a test is not currently being conducted to predict prospectively response to therapy for this diverse disease set.
The identification of tumor cells expressing P-gp or exhibiting positive P-gp function involves a relationship between negative and positive control situations.
Expression assays that use antibodies to detect P-gp expression include controls of cells either not treated with primary antibody, or cells treated with an antibody of the same isotype as that of the anti-P-gp reagent. At a cutoff where cells treated under these latter conditions exhibited minimal positive reaction, e.g., 0-5% positive cells, positive results using the anti-P-gp antibody include 10% or more positive cells, typically 10-25%
positive cells. Functional assays involve a ratio of P-gp dye accumulation or efflux in the presence and absence of a specific P-gp inhibitor such as zosuquidar. For the accumulation assay format the amount of dye taken up by the cells in the presence of zosuquidar is divided by that amount of dye taken up by cells cultured without zosuquidar. For the efflux assay format the amount of dye eliminated from the cells in the presence of zosuquidar is divided by that amount of dye eliminated without zosuquidar in the culture. Positive P-gp functional activity is inferred for ratios greater than about 1:1.2, typically ratios of from about 1:1.2 to about 1:1.5. For the efflux P-gp functional assay, ratios can be used, as well as % efflux and % inhibition of efflux by zosuquidar or other P-gp modulators. Positive P-gp functional activity is inferred by % efflux of from about 30% to about 50%, and specific inhibition by a P-gp modulator is similarly from about 30% to about 50%.
Chemotherapeutic Regimens Utilizing Zosuquidar and Mylotar~
In preferred embodiments, a P-gp expression or efflux pump activity diagnostic is conducted to provide information in treating AML patients or patients with metastatic breast cancer with zosuquidar in combination with Mylotarg. If the results of the P-gp expression or efflux pump activity diagnostic indicates positive P-gp expression or efflux pump activity, then treatment with zosuquidar (or another P-gp efflux inhibitor) in combination with Mylotarg is initiated. If the results of the P-gp expression or efflux pump activity diagnostic indicate negative P-gp expression or efflux pump activity, then zosuquidar is expected not to yield an improvement in clinical outcome and another treatment option not involving administration of a P-gp efflux inhibitor is selected. In relapsed AML patients, it is generally considered acceptable clinical practice to wait for P-gp expression or efflux pump activity test results before initiating a treatment.
However, in certain embodiments it can be desirable to initiate treatment before receiving test results, and then reevaluate the desirability of continuing treatment, depending upon the test results. Most preferably, P-gp expression or efflux pump activity of a sample both in the presence and absence of the P-gp efflux inhibitor is compared, whereby the P-gp efflux that is inhibitable by the P-gp efflux inhibitor can be determined.
However, in certain embodiments wherein P-gp expression or function status correlates with expectation of clinical success, it can be useful to determine P-gp expression or efflux pump activity at any point in time.
Mylotarg was approved in May 2000 for relapsed CD33-positive AML patients over the age of 60. Mylotarg from Wyeth and Celltech is based on antibody-targeted chemotherapy. Mylotarg's highly specific antibody recognizes a cell-surface molecule, CD33, which is abundant on AML cells (>90%) but absent from norinal blood stem cells, the seeds from which normal blood and immune cells originate. The antibody is linked to calicheamicin, a potent chemotherapy agent. The antibody selectively targets leukemic blast cells and delivers calicheamicin to them. The chemical structure of Mylotarg is provided below.
n, average loading of hP67.6 callicheamicln derivative on antibody, is 2 to 3 moleslmole NtJ
NHNA'A hif~=~ C7 G~#;~
~~~ O CH3 O NH .f, O
0 OCM3 ON HN C3~
~O H
OCH3 CH2Cll x Ft+~a O a {~
~}"~3 v("'SIr1 CH3 1 OCH, 0 n There is a growing body of evidence to suggest that the calicheamicin component of Mylotarg is also an MDR substrate and subject to the P-gp efflux pump. In several studies, the cytotoxic effect of Mylotarg has been shown to be inversely correlated with the amount of P-gp present. Two MDR modulators, valspodar and the quinolone derivative MS-209, have both been shown to reverse the resistance to Mylotarg in P-gp expressing CD33(+) leukemia cells and clinical studies are underway in combination with cyclosporine.
The combination of zosuquidar, a highly specific and safe P-gp efflux inhibitor, in combination with Mylotarg or another calicheamicin-antibody conjugate is effective for treatment of relapsed AML. The effective dose of zosuquidar and the timing of administration of zosuquidar and Mylotarg are critical to achieving improved complete remission rates and enhanced leukemia free and overall survival rates in the relapsed AML patient population. While the methods and formulations of preferred embodiments are especially preferred for treatment of relapsed AML patients, the methods and formulations can be adapted to other drugs and indications. For example, P-gp efflux inhibitors other than zosuquidar and/or chemotherapeutics other than Mylotarg can be administered according to the disclosed dosing regimens, or slightly modified dosing regimens. Likewise, the formulations and dosing regimens employing zosuquidar and Mylotarg can be employed in treating AML patients other than relapsed AML
patients, or for other types of leukemia or other cancers that express P-gp, e.g., many solid tumors, lymphomas, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, myeloma, lymphocytic leukemia, breast cancer, and sarcoma.
Zosuquidar or certain other therapeutic agents can be administered in the form of a pharmaceutically acceptable salt, e.g., the trihydrochloride salt. The terms "pharmaceutically acceptable salts" and "a pharmaceutically acceptable salt thereof' as used herein are broad terms and are used in their ordinary sense, including, without limitation, to refer to salts prepared from pharmaceutically acceptable, non-toxic acids or bases. Suitable pharmaceutically acceptable salts include metallic salts, e.g., salts of aluminum, zinc, alkali metal salts such as lithium, sodium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts; organic salts, e.g., salts of lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine, and tris; salts of free acids and bases; inorganic salts, e.g., sulfate, hydrochloride, and hydrobromide;
and other salts which are currently in widespread pharmaceutical use and are listed in sources well known to those of skill in the art, such as, for exainple, The Merck Index.
Any suitable constituent can be selected to make a salt of zosuquidar or other therapeutic agents discussed herein, provided that it is non-toxic and does not substantially interfere with the desired activity. In addition to salts, pharmaceutically acceptable precursors and derivatives of the compounds can be employed. Pharmaceutically acceptable amides, lower alkyl esters, and protected derivatives can also be suitable for use in compositions and methods of preferred embodiments. Also suitable for administration are selected therapeutic agents in hydrated form, selected enantiomeric forms of certain therapeutic agents, racemic mixtures of certain therapeutic agents, and the like.
Contemplated routes of administration include topical, oral, subcutaneous, parenteral, intradermal, intramuscular, intraperitoneal, and intravenous.
However, it is particularly preferred to administer zosuquidar and/or Mylotarg in intravenous form. The combination or individual components can be in any suitable solid or liquid form. A
particularly preferred form comprises a lyophilized form that is reconstituted for intravenous administration.
Zosuquidar and/or other therapeutic agents can be formulated into liquid preparations for, e.g., oral, nasal, anal, rectal, buccal, vaginal, peroral, intragastric, mucosal, perlingual, alveolar, gingival, olfactory, or respiratory mucosa administration.
Suitable forms for such administration include suspensions, syrups, and elixirs. If nasal or respiratory (mucosal) administration is desired (e.g., aerosol inhalation or insufflation), compositions may be in a form and dispensed by a squeeze spray dispenser, pump dispenser or aerosol dispenser. Aerosols are usually under pressure by means of a hydrocarbon. Pump dispensers can preferably dispense a metered dose or a dose having a particular particle size.
The pharmaceutical compositions containing zosuquidar and/or other therapeutic agents are preferably isotonic with the blood or other body fluid of the patient. The isotonicity of the compositions can be attained using sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride is particularly preferred.
Buffering agents can be employed, such as acetic acid and salts thereof, citric acid and salts thereof, boric acid and salts thereof, and phosphoric acid and salts thereof.
Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based. on Ringer's dextrose), and the like.
Viscosity of the pharmaceutical compositions can be maintained at a selected level using a pharmaceutically acceptable thickening agent. Methylcellulose is preferred because it is readily and economically available and is easy to work with.
Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The preferred concentration of the thickener can depend upon the thickening agent selected. An amount is preferably used that can achieve the selected viscosity. Viscous compositions are normally prepared from solutions by the addition of such thickening agents.
A pharmaceutically acceptable preservative can be employed to increase the shelf life of the pharmaceutical compositions. Benzyl alcohol can be suitable, although a variety of preservatives including, for example, parabens, thimerosal, chlorobutanol, and benzalkonium chloride can also be employed. A suitable concentration of the preservative is typically from about 0.02% to about 2% based on the total weight of the composition, although larger or smaller amounts can be desirable depending upon the agent selected.
The zosuquidar and/or other therapeutic agents can be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, and the like, and can contain auxiliary substances such as wetting or emulsifying agents, pH
buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. See, e.g., standards texts such as "Remington: The Science and Practice of Pharmacy", Lippincott Williams & Wilkins; 20th edition (June 1, 2003) and "Remington's Pharmaceutical Sciences," Mack Pub. Co.; 18th and 19th editions (December 1985, and June 1990, respectively). Such preparations can include 'complexing agents, metal ions, polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, and the like, liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts.
Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like.
The presence of such additional components can influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance, and are thus chosen according to the intended application, such that the characteristics of the carrier are tailored to the selected route of administration.
For oral administration, the zosuquidar and/or other therapeutic agents can be provided as a tablet, aqueous or oil suspension, dispersible powder or granule, emulsion, hard or soft capsule, syrup, or elixir. Compositions intended for oral administration can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and can include one or more of the following agents:
patients, or for other types of leukemia or other cancers that express P-gp, e.g., many solid tumors, lymphomas, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, myeloma, lymphocytic leukemia, breast cancer, and sarcoma.
Zosuquidar or certain other therapeutic agents can be administered in the form of a pharmaceutically acceptable salt, e.g., the trihydrochloride salt. The terms "pharmaceutically acceptable salts" and "a pharmaceutically acceptable salt thereof' as used herein are broad terms and are used in their ordinary sense, including, without limitation, to refer to salts prepared from pharmaceutically acceptable, non-toxic acids or bases. Suitable pharmaceutically acceptable salts include metallic salts, e.g., salts of aluminum, zinc, alkali metal salts such as lithium, sodium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts; organic salts, e.g., salts of lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine, and tris; salts of free acids and bases; inorganic salts, e.g., sulfate, hydrochloride, and hydrobromide;
and other salts which are currently in widespread pharmaceutical use and are listed in sources well known to those of skill in the art, such as, for exainple, The Merck Index.
Any suitable constituent can be selected to make a salt of zosuquidar or other therapeutic agents discussed herein, provided that it is non-toxic and does not substantially interfere with the desired activity. In addition to salts, pharmaceutically acceptable precursors and derivatives of the compounds can be employed. Pharmaceutically acceptable amides, lower alkyl esters, and protected derivatives can also be suitable for use in compositions and methods of preferred embodiments. Also suitable for administration are selected therapeutic agents in hydrated form, selected enantiomeric forms of certain therapeutic agents, racemic mixtures of certain therapeutic agents, and the like.
Contemplated routes of administration include topical, oral, subcutaneous, parenteral, intradermal, intramuscular, intraperitoneal, and intravenous.
However, it is particularly preferred to administer zosuquidar and/or Mylotarg in intravenous form. The combination or individual components can be in any suitable solid or liquid form. A
particularly preferred form comprises a lyophilized form that is reconstituted for intravenous administration.
Zosuquidar and/or other therapeutic agents can be formulated into liquid preparations for, e.g., oral, nasal, anal, rectal, buccal, vaginal, peroral, intragastric, mucosal, perlingual, alveolar, gingival, olfactory, or respiratory mucosa administration.
Suitable forms for such administration include suspensions, syrups, and elixirs. If nasal or respiratory (mucosal) administration is desired (e.g., aerosol inhalation or insufflation), compositions may be in a form and dispensed by a squeeze spray dispenser, pump dispenser or aerosol dispenser. Aerosols are usually under pressure by means of a hydrocarbon. Pump dispensers can preferably dispense a metered dose or a dose having a particular particle size.
The pharmaceutical compositions containing zosuquidar and/or other therapeutic agents are preferably isotonic with the blood or other body fluid of the patient. The isotonicity of the compositions can be attained using sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride is particularly preferred.
Buffering agents can be employed, such as acetic acid and salts thereof, citric acid and salts thereof, boric acid and salts thereof, and phosphoric acid and salts thereof.
Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based. on Ringer's dextrose), and the like.
Viscosity of the pharmaceutical compositions can be maintained at a selected level using a pharmaceutically acceptable thickening agent. Methylcellulose is preferred because it is readily and economically available and is easy to work with.
Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The preferred concentration of the thickener can depend upon the thickening agent selected. An amount is preferably used that can achieve the selected viscosity. Viscous compositions are normally prepared from solutions by the addition of such thickening agents.
A pharmaceutically acceptable preservative can be employed to increase the shelf life of the pharmaceutical compositions. Benzyl alcohol can be suitable, although a variety of preservatives including, for example, parabens, thimerosal, chlorobutanol, and benzalkonium chloride can also be employed. A suitable concentration of the preservative is typically from about 0.02% to about 2% based on the total weight of the composition, although larger or smaller amounts can be desirable depending upon the agent selected.
The zosuquidar and/or other therapeutic agents can be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, and the like, and can contain auxiliary substances such as wetting or emulsifying agents, pH
buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. See, e.g., standards texts such as "Remington: The Science and Practice of Pharmacy", Lippincott Williams & Wilkins; 20th edition (June 1, 2003) and "Remington's Pharmaceutical Sciences," Mack Pub. Co.; 18th and 19th editions (December 1985, and June 1990, respectively). Such preparations can include 'complexing agents, metal ions, polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, and the like, liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts.
Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like.
The presence of such additional components can influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance, and are thus chosen according to the intended application, such that the characteristics of the carrier are tailored to the selected route of administration.
For oral administration, the zosuquidar and/or other therapeutic agents can be provided as a tablet, aqueous or oil suspension, dispersible powder or granule, emulsion, hard or soft capsule, syrup, or elixir. Compositions intended for oral administration can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and can include one or more of the following agents:
sweeteners, flavoring agents, coloring agents and preservatives. Aqueous suspensions can contain the active ingredient in admixture with excipients suitable for the manufacture of aqueous suspensions.
Formulations for oral administration can also be provided as hard gelatin capsules, wherein the zosuquidar and/or other active ingredients are mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules. In soft capsules, the active ingredients can be dissolved or suspended in suitable liquids, such as water or an oil medium, such as peanut oil, olive oil, fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers and microspheres formulated for oral administration can also be used. Capsules can include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc and magnesium stearate and, optionally, stabilizers.
Tablets can be uncoated or coated by known methods to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time. For example, a time delay material such as glyceryl monostearate can be used. When administered in solid form, such as tablet form, the solid form typically comprises from about 0.001 wt. % or less to about 50 wt. % or more of active ingredient(s) including zosuquidar and/or other therapeutic agents, preferably from about 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 wt. % to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, or 45 wt. %.
Tablets can contain the zosuquidar and/or other therapeutic agents in admixture with non-toxic pharmaceutically acceptable excipients including inert materials. For example, a tablet can be prepared by compression or molding, optionally, with one or more additional ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent.
Molded tablets can be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
Preferably, each tablet or capsule contains from about 10 mg or less to about 1,000 mg or more of each of zosuquidar and/or other therapeutic agents, more preferably from about 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg to about 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, or 900 mg. Most preferably, tablets or capsules are provided in a range of dosages to permit divided dosages to be administered. A
dosage appropriate to the patient and the number of doses to be administered daily can thus be conveniently selected. While in certain embodiments it can be preferred to incorporate the zosuquidar and any other therapeutic agent employed in combination therewith in a single tablet or other dosage form, in certain embodiments it can be desirable to provide the zosuquidar and other therapeutic agents in separate dosage forms, e.g., zosuquidar in a dosage form separate from other agents(s). Combinations of dosage forms can also be employed, e.g., oral and intravenous.
Suitable inert materials include diluents, such as carbohydrates, mannitol, lactose, anhydrous lactose, cellulose, sucrose, modified dextrans, starch, and the like, and inorganic salts such as calcium triphosphate, calcium phosphate, sodium phosphate, calcium carbonate, sodium carbonate, magnesium carbonate, and sodium chloride.
Disintegrants or granulating agents can be included in the formulation, for example, starches such as corn starch, alginic acid, sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite, insoluble cationic exchange resins, powdered gums such as agar, karaya, and tragacanth, and alginic acid and salts thereof.
Binders can be used to form a hard tablet. Binders include materials from natural products such as acacia, tragacanth, starch, gelatin, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, and the like.
Lubricants, such as stearic acid and magnesium or calcium salts thereof, polytetrafluoroethylene, liquid paraffin, vegetable oils, waxes, sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol, starch, talc, pyrogenic silica, hydrated silicoaluminate, and the like can be included in tablet formulations.
Surfactants can also be employed, for example, anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate, and. dioctyl sodium sulfonate, cationic detergents such as benzalkonium chloride and benzethonium chloride, and/or nonionic detergents such as polyoxyethylene hydrogenated castor oil, glycerol monostearate, polysorbates, sucrose fatty acid ester, methyl cellulose, and carboxymethyl cellulose.
Formulations for oral administration can also be provided as hard gelatin capsules, wherein the zosuquidar and/or other active ingredients are mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules. In soft capsules, the active ingredients can be dissolved or suspended in suitable liquids, such as water or an oil medium, such as peanut oil, olive oil, fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers and microspheres formulated for oral administration can also be used. Capsules can include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc and magnesium stearate and, optionally, stabilizers.
Tablets can be uncoated or coated by known methods to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time. For example, a time delay material such as glyceryl monostearate can be used. When administered in solid form, such as tablet form, the solid form typically comprises from about 0.001 wt. % or less to about 50 wt. % or more of active ingredient(s) including zosuquidar and/or other therapeutic agents, preferably from about 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 wt. % to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, or 45 wt. %.
Tablets can contain the zosuquidar and/or other therapeutic agents in admixture with non-toxic pharmaceutically acceptable excipients including inert materials. For example, a tablet can be prepared by compression or molding, optionally, with one or more additional ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent.
Molded tablets can be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
Preferably, each tablet or capsule contains from about 10 mg or less to about 1,000 mg or more of each of zosuquidar and/or other therapeutic agents, more preferably from about 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg to about 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, or 900 mg. Most preferably, tablets or capsules are provided in a range of dosages to permit divided dosages to be administered. A
dosage appropriate to the patient and the number of doses to be administered daily can thus be conveniently selected. While in certain embodiments it can be preferred to incorporate the zosuquidar and any other therapeutic agent employed in combination therewith in a single tablet or other dosage form, in certain embodiments it can be desirable to provide the zosuquidar and other therapeutic agents in separate dosage forms, e.g., zosuquidar in a dosage form separate from other agents(s). Combinations of dosage forms can also be employed, e.g., oral and intravenous.
Suitable inert materials include diluents, such as carbohydrates, mannitol, lactose, anhydrous lactose, cellulose, sucrose, modified dextrans, starch, and the like, and inorganic salts such as calcium triphosphate, calcium phosphate, sodium phosphate, calcium carbonate, sodium carbonate, magnesium carbonate, and sodium chloride.
Disintegrants or granulating agents can be included in the formulation, for example, starches such as corn starch, alginic acid, sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite, insoluble cationic exchange resins, powdered gums such as agar, karaya, and tragacanth, and alginic acid and salts thereof.
Binders can be used to form a hard tablet. Binders include materials from natural products such as acacia, tragacanth, starch, gelatin, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, and the like.
Lubricants, such as stearic acid and magnesium or calcium salts thereof, polytetrafluoroethylene, liquid paraffin, vegetable oils, waxes, sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol, starch, talc, pyrogenic silica, hydrated silicoaluminate, and the like can be included in tablet formulations.
Surfactants can also be employed, for example, anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate, and. dioctyl sodium sulfonate, cationic detergents such as benzalkonium chloride and benzethonium chloride, and/or nonionic detergents such as polyoxyethylene hydrogenated castor oil, glycerol monostearate, polysorbates, sucrose fatty acid ester, methyl cellulose, and carboxymethyl cellulose.
Controlled-release formulations can be employed wherein the zosuquidar and/or other therapeutic agents are incorporated into an inert matrix that permits release by either diffusion or leaching mechanisms. Slowly degenerating matrices can also be incorporated into the formulation. Other delivery systems can include timed release, delayed release, or sustained release delivery systems. Nanoparticulate systems or nanoparticulate forms of the active ingredients can advantageously be employed in certain embodiments.
Coatings can be used, for example, nonenteric materials such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone, polyethylene glycols, and enteric materials such as phthalic acid esters.
Dyestuffs and pigments can be added for identification or to characterize different combinations of active compound doses When administered orally in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils can be added to the zosuquidar and/or other therapeutic agents.
Physiological saline solution, dextrose, other saccharide solutions, and glycols such as etliylene glycol, propylene glycol, and polyethylene glycol are also suitable liquid carriers.
The pharmaceutical compositions can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, such as olive or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof. Suitable emulsifying agents include naturally-occurring gums such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsions can also contain sweetening and flavoring agents.
Pulmonary delivery of zosuquidar and/or other therapeutic agents can also be employed. The zosuquidar and/or other therapeutic agents are delivered to the lungs while inhaling and traverse across the lung epithelial lining to the blood stream. A wide range of mechanical devices designed for pulmonary delivery of therapeutic products can be einployed, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. These devices employ formulations suitable for the dispensing of zosuquidar and/or other therapeutic agents.
Typically, each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants, and/or carriers useful in therapy.
The zosuquidar and/or other therapeutic agents are advantageously prepared for pulmonary delivery in particulate form with an average particle size of from 0.1 m or less to 10 m or more, more preferably from about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 m to about 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, or 9.5 m. Pharmaceutically acceptable carriers for pulmonary delivery of zosuquidar and/or other therapeutic agents include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations can include dipalmitoylphosphatidylcholine (DPPC), 1,2-sn-dioleoylphosphatidylcholine (DOPE), disteroylphosphatidylcholine (DSPC), and dioleoylphosphatidyl-choline (DOPC).
Natural or synthetic surfactants can be used, including polyethylene glycol and dextrans, such as cyclodextran. Bile salts and other related enhancers, as well as cellulose and cellulose derivatives, and amino acids can also be used. Liposomes, microcapsules, microspheres, inclusion complexes, and other types of carriers can also be employed.
Pharmaceutical formulations suitable for use with a nebulizer, either jet or ultrasonic, typically comprise the zosuquidar and/or other therapeutic agents dissolved or suspended in water at a concentration of about 0.01 mg or less to 100 mg or more of zosuquidar and/or other therapeutic agents per mL of solution, preferably from about 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg per mL of solution to about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 mg per mL of solution. The formulation can also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation can also contain a surfactant, to reduce or prevent surface induced aggregation of the zosuquidar and/or other therapeutic agents caused by atomization of the solution in forming the aerosol.
Formulations for use with a metered-dose inhaler device generally comprise a finely divided powder containing the active ingredients suspended in a propellant with the aid of a surfactant. The propellant can include conventional propellants, such as chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons, and hydrocarbons.
Preferred propellants include trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, 1,1,1,2-tetrafluoroethane, and combinations thereof. Suitable surfactants include sorbitan trioleate, soya lecithin, and oleic acid.
Coatings can be used, for example, nonenteric materials such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone, polyethylene glycols, and enteric materials such as phthalic acid esters.
Dyestuffs and pigments can be added for identification or to characterize different combinations of active compound doses When administered orally in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils can be added to the zosuquidar and/or other therapeutic agents.
Physiological saline solution, dextrose, other saccharide solutions, and glycols such as etliylene glycol, propylene glycol, and polyethylene glycol are also suitable liquid carriers.
The pharmaceutical compositions can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, such as olive or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof. Suitable emulsifying agents include naturally-occurring gums such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsions can also contain sweetening and flavoring agents.
Pulmonary delivery of zosuquidar and/or other therapeutic agents can also be employed. The zosuquidar and/or other therapeutic agents are delivered to the lungs while inhaling and traverse across the lung epithelial lining to the blood stream. A wide range of mechanical devices designed for pulmonary delivery of therapeutic products can be einployed, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. These devices employ formulations suitable for the dispensing of zosuquidar and/or other therapeutic agents.
Typically, each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants, and/or carriers useful in therapy.
The zosuquidar and/or other therapeutic agents are advantageously prepared for pulmonary delivery in particulate form with an average particle size of from 0.1 m or less to 10 m or more, more preferably from about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 m to about 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, or 9.5 m. Pharmaceutically acceptable carriers for pulmonary delivery of zosuquidar and/or other therapeutic agents include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations can include dipalmitoylphosphatidylcholine (DPPC), 1,2-sn-dioleoylphosphatidylcholine (DOPE), disteroylphosphatidylcholine (DSPC), and dioleoylphosphatidyl-choline (DOPC).
Natural or synthetic surfactants can be used, including polyethylene glycol and dextrans, such as cyclodextran. Bile salts and other related enhancers, as well as cellulose and cellulose derivatives, and amino acids can also be used. Liposomes, microcapsules, microspheres, inclusion complexes, and other types of carriers can also be employed.
Pharmaceutical formulations suitable for use with a nebulizer, either jet or ultrasonic, typically comprise the zosuquidar and/or other therapeutic agents dissolved or suspended in water at a concentration of about 0.01 mg or less to 100 mg or more of zosuquidar and/or other therapeutic agents per mL of solution, preferably from about 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg per mL of solution to about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 mg per mL of solution. The formulation can also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation can also contain a surfactant, to reduce or prevent surface induced aggregation of the zosuquidar and/or other therapeutic agents caused by atomization of the solution in forming the aerosol.
Formulations for use with a metered-dose inhaler device generally comprise a finely divided powder containing the active ingredients suspended in a propellant with the aid of a surfactant. The propellant can include conventional propellants, such as chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons, and hydrocarbons.
Preferred propellants include trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, 1,1,1,2-tetrafluoroethane, and combinations thereof. Suitable surfactants include sorbitan trioleate, soya lecithin, and oleic acid.
Formulations suitable for dispensing from a powder inhaler device typically comprise a finely divided dry powder containing zosuquidar and/or other therapeutic agents, optionally including a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in an amount that facilitates dispersal of the powder from the device, typically from about 1 wt. % or less to 99 wt. % or more of the formulation, preferably from about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 wt. % to about 55, 60, 65, 70, 75, 80, 85, or 90 wt. % of the formulation.
When zosuquidar and/or other therapeutic agents are administered by intravenous, cutaneous, subcutaneous, parenteral, or other injection, they are preferably in the form of pyrogen-free, parenterally acceptable aqueous solution or oleaginous suspension.
Suspensions can be formulated according to methods well known in the art using suitable dispersing or wetting agents and suspending agents. The preparation of acceptable aqueous solutions with suitable pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for injection preferably contains an isotonic vehicle such as 1,3-butanediol, water, isotonic sodium chloride solution, Ringer's solution, dextrose solution, dextrose and sodium chloride solution, lactated Ringer's solution, or other vehicles as are known in the art. In addition, sterile fixed oils can be employed conventionally as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed, including synthetic monoglycerides and diglycerides. In addition, fatty acids stich as oleic acid can likewise be used in the formation of injectable preparations. The pharmaceutical compositions can also contain stabilizers, preservatives, buffers, antioxidants, and other additives known to those of skill in the art.
The duration of the injection can be adjusted depending upon various factors, and can comprise a single injection administered over the course of a few seconds or less to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 32, 34, 36, 40, 44, 48, 54, 60, 66, 72, 78; 84, 90, or 96 hours or more of continuous intravenous administration.
The zosuquidar and/or other therapeutic agents can be administered systemically or locally, via a liquid or gel, or as an implant or device.
The coinpositions of the prefeiTed embodiments can additionally employ adjunct components conventionally found in pharmaceutical compositions in their art-established fashion and at their art-established levels. Thus, for example, the compositions can contain additional compatible pharmaceutically active materials for combination therapy (such as supplemental P-gp inhibitors, chemotherapeutic agents, and the like), or can contain materials useful in physically formulating various dosage forms of the preferred embodiments, such as excipients, dyes, perfumes, thickening agents, stabilizers, preservatives and antioxidants.
The zosuquidar and/or other therapeutic agents can be provided to an administering physician or other health care professional in the form of a kit. The kit is a package which houses one or more containers which contain zosuquidar and/or additional therapeutic agents in suitable form and instructions for administering the pharinaceutical composition to a subject. The kit can optionally also contain one or more additional I Q therapeutic agents. The kit can optionally contain one or more assays or diagnostic tools and instructions for use, e.g., a diagnostic to measure efflux pump activity or P-gp expression or function. For example, a kit containing a single composition comprising zosuquidar with one or more chemotherapeutic agents can be provided, or separate pharmaceutical coinpositions containing zosuquidar and other therapeutic agents can be provided. The kit can also contain separate doses of zosuquidar and/or other therapeutic agents for serial or sequential administration. The kit can contain suitable delivery devices, e.g., syringes, inhalation devices, and the like, along with instructions for administrating zosuquidar and/or other therapeutic agent. The kit can optionally contain instructions for storage, reconstitution (if applicable, e.g., for a lyophilized form reconstituted for intravenous administration), and administration of any or all therapeutic agents included. The kits can include a plurality of containers reflecting the number of administrations to be given to a subject. In a particularly preferred embodiment, a kit for the treatment of AML is provided that includes both zosuquidar, a chemotherapeutic agent, and one or more diagnostics or instructions for conducting one or more diagnostics for determining P-gp expression and/or efflux pump activity. In a particularly preferred embodiment, the kit includes a "zosuquidar drugable" assay, as previously described.
Zosuquidar and a therapeutic agent that is a substrate for P-gp efflux can be administered to patients suffering from AML prior to confirmation of P-gp expression or function, or to AML patients other than relapse AML patients. However, such therapy is preferably administered to relapsed AML patients. The administration route, amount administered, and frequency of administration can vary depending on the age of the patient, status as relapsed or newly diagnosed AML patient, and severity of the condition Contemplated amounts of Mylotarg for intravenous administration to treat relapsed AML are from about 10 mg/day or less to about 1000 mg/day or more administered on one, two, or more separate days. The dosage is preferably administered intravenously at a rate of about 1 mg/ma or less to about 10 mg/mz or more continuously over the course of about 2, 3, or 4 hours to about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours, more preferably over the course of about 2 hours to about 6 hours; however, administration at a rate of 5 mg/m2, 7 mg/m2, or 9 mg/m2 over about 2 hours is particularly preferred. Preferably, doses of Mylotarg are administered on Day 1 and Day 15 of the treatment regimen. However, in certain embodiments, the second dose can be adininistered on Day 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22, or another day of the treatment regimen. Other dosing regimens include administering three doses total over a week.
Contemplated amounts of zosuquidar for intravenous administration to treat relapsed AML are from about 400 mg/day or less to about 1,600 mg/day or more, preferably from about 500, 600, or 700 mg/day to about 900, 1000, 1100, 1200, 1300, 1400, or 1500 mg/day, and most preferably from about 500 mg/day to about 800 mg/day.
It is generally preferred to start the infusion of zosuquidar from about 2 hours or less to about 6 hours or more prior to the administration of Mylotarg. In the course of a treatment regimen, the zosuquidar is preferably administered on two, three, or four separate days. The dosage is preferably administered in intravenously continuously over the course of about 6 to 90 hours, more preferably over the course of 12, 18, 24, 30, 36, or 42 hours to about 54, 60, 66, 72, 78, or 84 hours, most preferably over about 24 hours, 48 hours, or 72 hours, depending upon the treatment regimen. Preferably the zosuquidar is administered on Day 1 of the treatment regimen. In certain embodiments, additional zosuquidar is administered on Day 2, on Days 2 and 3, or on Days 2, 15, and 16.
However, in certain embodiments, one, two, or three or more additional doses can be administered on other days of the treatment regimen.
Table 1 provides various dosing regimes that can be used in treating relapsed AML.
When zosuquidar and/or other therapeutic agents are administered by intravenous, cutaneous, subcutaneous, parenteral, or other injection, they are preferably in the form of pyrogen-free, parenterally acceptable aqueous solution or oleaginous suspension.
Suspensions can be formulated according to methods well known in the art using suitable dispersing or wetting agents and suspending agents. The preparation of acceptable aqueous solutions with suitable pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for injection preferably contains an isotonic vehicle such as 1,3-butanediol, water, isotonic sodium chloride solution, Ringer's solution, dextrose solution, dextrose and sodium chloride solution, lactated Ringer's solution, or other vehicles as are known in the art. In addition, sterile fixed oils can be employed conventionally as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed, including synthetic monoglycerides and diglycerides. In addition, fatty acids stich as oleic acid can likewise be used in the formation of injectable preparations. The pharmaceutical compositions can also contain stabilizers, preservatives, buffers, antioxidants, and other additives known to those of skill in the art.
The duration of the injection can be adjusted depending upon various factors, and can comprise a single injection administered over the course of a few seconds or less to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 32, 34, 36, 40, 44, 48, 54, 60, 66, 72, 78; 84, 90, or 96 hours or more of continuous intravenous administration.
The zosuquidar and/or other therapeutic agents can be administered systemically or locally, via a liquid or gel, or as an implant or device.
The coinpositions of the prefeiTed embodiments can additionally employ adjunct components conventionally found in pharmaceutical compositions in their art-established fashion and at their art-established levels. Thus, for example, the compositions can contain additional compatible pharmaceutically active materials for combination therapy (such as supplemental P-gp inhibitors, chemotherapeutic agents, and the like), or can contain materials useful in physically formulating various dosage forms of the preferred embodiments, such as excipients, dyes, perfumes, thickening agents, stabilizers, preservatives and antioxidants.
The zosuquidar and/or other therapeutic agents can be provided to an administering physician or other health care professional in the form of a kit. The kit is a package which houses one or more containers which contain zosuquidar and/or additional therapeutic agents in suitable form and instructions for administering the pharinaceutical composition to a subject. The kit can optionally also contain one or more additional I Q therapeutic agents. The kit can optionally contain one or more assays or diagnostic tools and instructions for use, e.g., a diagnostic to measure efflux pump activity or P-gp expression or function. For example, a kit containing a single composition comprising zosuquidar with one or more chemotherapeutic agents can be provided, or separate pharmaceutical coinpositions containing zosuquidar and other therapeutic agents can be provided. The kit can also contain separate doses of zosuquidar and/or other therapeutic agents for serial or sequential administration. The kit can contain suitable delivery devices, e.g., syringes, inhalation devices, and the like, along with instructions for administrating zosuquidar and/or other therapeutic agent. The kit can optionally contain instructions for storage, reconstitution (if applicable, e.g., for a lyophilized form reconstituted for intravenous administration), and administration of any or all therapeutic agents included. The kits can include a plurality of containers reflecting the number of administrations to be given to a subject. In a particularly preferred embodiment, a kit for the treatment of AML is provided that includes both zosuquidar, a chemotherapeutic agent, and one or more diagnostics or instructions for conducting one or more diagnostics for determining P-gp expression and/or efflux pump activity. In a particularly preferred embodiment, the kit includes a "zosuquidar drugable" assay, as previously described.
Zosuquidar and a therapeutic agent that is a substrate for P-gp efflux can be administered to patients suffering from AML prior to confirmation of P-gp expression or function, or to AML patients other than relapse AML patients. However, such therapy is preferably administered to relapsed AML patients. The administration route, amount administered, and frequency of administration can vary depending on the age of the patient, status as relapsed or newly diagnosed AML patient, and severity of the condition Contemplated amounts of Mylotarg for intravenous administration to treat relapsed AML are from about 10 mg/day or less to about 1000 mg/day or more administered on one, two, or more separate days. The dosage is preferably administered intravenously at a rate of about 1 mg/ma or less to about 10 mg/mz or more continuously over the course of about 2, 3, or 4 hours to about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours, more preferably over the course of about 2 hours to about 6 hours; however, administration at a rate of 5 mg/m2, 7 mg/m2, or 9 mg/m2 over about 2 hours is particularly preferred. Preferably, doses of Mylotarg are administered on Day 1 and Day 15 of the treatment regimen. However, in certain embodiments, the second dose can be adininistered on Day 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, or 22, or another day of the treatment regimen. Other dosing regimens include administering three doses total over a week.
Contemplated amounts of zosuquidar for intravenous administration to treat relapsed AML are from about 400 mg/day or less to about 1,600 mg/day or more, preferably from about 500, 600, or 700 mg/day to about 900, 1000, 1100, 1200, 1300, 1400, or 1500 mg/day, and most preferably from about 500 mg/day to about 800 mg/day.
It is generally preferred to start the infusion of zosuquidar from about 2 hours or less to about 6 hours or more prior to the administration of Mylotarg. In the course of a treatment regimen, the zosuquidar is preferably administered on two, three, or four separate days. The dosage is preferably administered in intravenously continuously over the course of about 6 to 90 hours, more preferably over the course of 12, 18, 24, 30, 36, or 42 hours to about 54, 60, 66, 72, 78, or 84 hours, most preferably over about 24 hours, 48 hours, or 72 hours, depending upon the treatment regimen. Preferably the zosuquidar is administered on Day 1 of the treatment regimen. In certain embodiments, additional zosuquidar is administered on Day 2, on Days 2 and 3, or on Days 2, 15, and 16.
However, in certain embodiments, one, two, or three or more additional doses can be administered on other days of the treatment regimen.
Table 1 provides various dosing regimes that can be used in treating relapsed AML.
Table 1.
Dose Mylotarg Zosuquidar Level -1 * 5 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 24 hr Day 1 and 15 1 5 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 48 hr Day 1&2 and 15&16 2 7 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 48 hr Day 1&2 and 15&16 3 9 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 48 hr Day 1&2 and 15&16 4 9 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 72 hr Day 1-3 and 15-17 * Only if level 1 has a dose limiting toxicity (DLT).
Table 2 provides alternative dosing regimes that can be used in treating relapsed AML.
Table 2.
Dose Mylotarg Zosuquidar Level -1 * 5 mg/m2 IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 24 hr Day l and 15 1 5 mg/m2 IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 48 15 hr Day 1&2 and 15&16 2 7 mg/m2 IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 48 15 hr Day 1&2 and 15&16 3 9 mg/m2 IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 48 15 hr Day l&2 and 15&16 4 9 mg/ma IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 72 15 hr Day l-3 and 15-17 * Only if level 1 has a dose limiting toxicity (DLT).
10 A clinical study was conducted to determine the efficacy of Mylotarg in the treatment of relapsed AML. It was determined that the rate of complete remission (CR +
Dose Mylotarg Zosuquidar Level -1 * 5 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 24 hr Day 1 and 15 1 5 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 48 hr Day 1&2 and 15&16 2 7 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 48 hr Day 1&2 and 15&16 3 9 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 48 hr Day 1&2 and 15&16 4 9 mg/m2 IV over 4 hr Day 1 and 15 800 mg/day continuous IV over 72 hr Day 1-3 and 15-17 * Only if level 1 has a dose limiting toxicity (DLT).
Table 2 provides alternative dosing regimes that can be used in treating relapsed AML.
Table 2.
Dose Mylotarg Zosuquidar Level -1 * 5 mg/m2 IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 24 hr Day l and 15 1 5 mg/m2 IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 48 15 hr Day 1&2 and 15&16 2 7 mg/m2 IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 48 15 hr Day 1&2 and 15&16 3 9 mg/m2 IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 48 15 hr Day l&2 and 15&16 4 9 mg/ma IV over 6-24 hr Day 1 and 500-700 mg/day continuous IV over 72 15 hr Day l-3 and 15-17 * Only if level 1 has a dose limiting toxicity (DLT).
10 A clinical study was conducted to determine the efficacy of Mylotarg in the treatment of relapsed AML. It was determined that the rate of complete remission (CR +
CRp) for P-gp negative patients treated with Mylotarg was 64% (N=36). In contrast, the rate of complete remission for P-gp positive patients was only 9% (N=22). This indicates that P-gp efflux plays an important role in survival rates for relapsed AML, and further indicates that inhibition of P-gp efflux, e.g., by also administering zosuquidar or another P-gp efflux inhibitor, has the potential to significantly improve response rates in P-gp positive patients. The diagnostic and assay methods described herein are therefore useful in treating relapsed AML. Likewise, a diagnostic or assay to determine P-gp expression or function or efflux pump activity can be useful in devising treatment regimens for other cancers, such as metastatic breast cancer, that also exhibit P-gp expression.
Chemotherapeutic Regimens Utilizing Zosuquidar Daunorubicin, and Cytarabine In preferred embodiments, a P-gp expression or efflux pump activity diagnostic is conducted to provide information in treating newly diagnosed AML patients with zosuquidar in combination with daunorubicin and cytarabine. In newly diagnosed AML
patients, it is generally not considered acceptable clinical practice to wait for P-gp expression or efflux pump activity test results before initiating a treatment.
Accordingly, treatment is initiated immediately after diagnosis. When test results become available, the desirability of continuing treatment can be evaluated, depending upon the test results.
Typically, when the results of the P-gp expression or efflux pump activity diagnostic indicate negative P-gp expression, then treatment with a P-gp efflux inhibitor is discontinued because administration of the drug is not expected to contribute to an improved clinical outcome. Preferably, P-gp expression or function or efflux pump activity is deterinined both in the presence and the absence the P-gp efflux inhibitor to determine the P-gp expression that is inhibitable by the P-gp efflux inhibitor.
Daunorubicin is an antibiotic chemotherapy treatment that is widely used to treat acute myeloid leulcemia and acute lymphocytic leukemia. It is produced by the bacteria Streptomyces coeruleorubidis and was approved by the FDA as a first line therapy treatment for leukemia in 1998. Daunorubicin is typically administered intravenously. It is marketed under the brand names Cerubidine, DaunoXome, and Liposomal daunorubicin. Daunorubicin has the following structure:
Chemotherapeutic Regimens Utilizing Zosuquidar Daunorubicin, and Cytarabine In preferred embodiments, a P-gp expression or efflux pump activity diagnostic is conducted to provide information in treating newly diagnosed AML patients with zosuquidar in combination with daunorubicin and cytarabine. In newly diagnosed AML
patients, it is generally not considered acceptable clinical practice to wait for P-gp expression or efflux pump activity test results before initiating a treatment.
Accordingly, treatment is initiated immediately after diagnosis. When test results become available, the desirability of continuing treatment can be evaluated, depending upon the test results.
Typically, when the results of the P-gp expression or efflux pump activity diagnostic indicate negative P-gp expression, then treatment with a P-gp efflux inhibitor is discontinued because administration of the drug is not expected to contribute to an improved clinical outcome. Preferably, P-gp expression or function or efflux pump activity is deterinined both in the presence and the absence the P-gp efflux inhibitor to determine the P-gp expression that is inhibitable by the P-gp efflux inhibitor.
Daunorubicin is an antibiotic chemotherapy treatment that is widely used to treat acute myeloid leulcemia and acute lymphocytic leukemia. It is produced by the bacteria Streptomyces coeruleorubidis and was approved by the FDA as a first line therapy treatment for leukemia in 1998. Daunorubicin is typically administered intravenously. It is marketed under the brand names Cerubidine, DaunoXome, and Liposomal daunorubicin. Daunorubicin has the following structure:
OM e 0 OH 0- H---CHz-CHM..Cil---CH-CH.v'HCS
Cytarabine is a deoxycytidine analogue, cytosine arabinoside (ara-C), which is metabolically activated to the triphosphate nucleotide (ara-CTP), which acts as a competitive inhibitor of DNA polymerase and produces S phase-specific cytotoxicity. It is used as an antineoplastic, generally as part of a combination chemotherapy regimen, in the treatment of acute' lymphocytic and acute myelogenous leulcemia, the blast phase of chronic myelogenous leukemia, erythroleukemia, and non-Hodgkin's lymphoma. It is typically administered intravenously and subcutaneously, and for the prophylaxis and treatment of meningeal leukemia, administered intrathecally. Cytarabine has the following structure:
H
HCH', OH
The combination of zosuquidar, the antibiotic chemotherapeutic daunorubicin, and the antineoplastic cytarabine, is effective for treatment of newly diagnosed AML. The effective dose of zosuquidar and the timing of administration of zosuquidar, daunorubicin, and cytarabine are critical to achieving improved coinplete remission rates and enhanced leukemia free survival rates in the newly diagnosed AML patient population. While the methods and formulations of preferred embodiments are especially preferred for treatment of newly diagnosed AML patients, the methods and formulations can be adapted to other drugs and indications. For example, P-gp efflux inhibitors other than zosuquidar and/or chemotherapeutics other than daunorubicin and cytarabine can be administered according to the disclosed dosing regimens, or slightly modified dosing regimens. Likewise, the formulations and dosing regimens employing zosuquidar, daunorubicin, and cytarabine can be employed in treating AML patients other than newly diagnosed AML patients, or for treating other types of leukemia or other cancers that exhibit P-gp expression, as discussed above.
Zosuquidar, daunorubicin, and cytarabine can be formulated as described above for zosuquidar and Mylotarg, and can be included in kits, also as described above.
The zosuquidar, daunorubicin, and/or cytarabine can be to patients suffering from AML prior to confirmation of the P-gp expression or function, or to AML
patients other than newly diagnosed AML patients (e.g., relapsed AML patients). However, therapy is preferably administered to newly diagnosed AML patients. The administration route, amount administered, and frequency of administration can vary depending on the age of the patient, status as relapsed or newly diagnosed AML patient, and severity of the condition.
Contemplated amounts of zosuquidar for intravenous administration to treat newly diagnosed AML are from about 400 mg/day or less to about 1,600 mg/day or more, preferably from about 500, 600, or 700 mg/day to about 900, 1000, 1100, 1200, 1300, 1400, or 1500 mg/day, and most preferably 700 mg/day. In the course of a treatment regimen, the zosuquidar is preferably administered on two, three, or four separate days.
The dosage is preferably administered in intravenously continuously over the course of about 6 to about 90 hours, more preferably over the course of about 12, 18, 24, 30, 36, or 42 hours to about 54, 60, 66, 72, 78, or 84 hours, most preferably over about 24 hours, 48 hours, or 72 hours, depending upon the treatment regimen. Preferably the zosuquidar is administered on Day 1 of the treatment regimen. In certain embodiments, additional zosuquidar is administered on Day 2, on Days 2 and 3, or on Days 2, 15, and 16.
However, in certain embodiments, one, two, or three or more additional doses can be administered on other days of the treatment regimen.
Contemplated amounts of daunorubicin for intravenous administration to treat newly diagnosed AML are from about 10 mg/m2/day or less to about 100 ing/m2/day or more administered at initiation of zosuquidar infusion or up to about 1, 2, 3, 4, 5, or 6 or more hours after initiation of zosuquidar infusion. The dosage is preferably administered intravenously at a rate of about 25 mg/m2/day or less to about 90 mg/m2/day or more, preferably about 30, 35, or 40 mg/m2/day or less to about 50, 55, 60, 65, 70, 75, 80, or 85 mg/m2 /day, and most preferably about 45 mg/mz/day continuously over the course of about 2 or 2.5 days to about 3.5 or 4 days, preferably about 3 days.
Cytarabine is a deoxycytidine analogue, cytosine arabinoside (ara-C), which is metabolically activated to the triphosphate nucleotide (ara-CTP), which acts as a competitive inhibitor of DNA polymerase and produces S phase-specific cytotoxicity. It is used as an antineoplastic, generally as part of a combination chemotherapy regimen, in the treatment of acute' lymphocytic and acute myelogenous leulcemia, the blast phase of chronic myelogenous leukemia, erythroleukemia, and non-Hodgkin's lymphoma. It is typically administered intravenously and subcutaneously, and for the prophylaxis and treatment of meningeal leukemia, administered intrathecally. Cytarabine has the following structure:
H
HCH', OH
The combination of zosuquidar, the antibiotic chemotherapeutic daunorubicin, and the antineoplastic cytarabine, is effective for treatment of newly diagnosed AML. The effective dose of zosuquidar and the timing of administration of zosuquidar, daunorubicin, and cytarabine are critical to achieving improved coinplete remission rates and enhanced leukemia free survival rates in the newly diagnosed AML patient population. While the methods and formulations of preferred embodiments are especially preferred for treatment of newly diagnosed AML patients, the methods and formulations can be adapted to other drugs and indications. For example, P-gp efflux inhibitors other than zosuquidar and/or chemotherapeutics other than daunorubicin and cytarabine can be administered according to the disclosed dosing regimens, or slightly modified dosing regimens. Likewise, the formulations and dosing regimens employing zosuquidar, daunorubicin, and cytarabine can be employed in treating AML patients other than newly diagnosed AML patients, or for treating other types of leukemia or other cancers that exhibit P-gp expression, as discussed above.
Zosuquidar, daunorubicin, and cytarabine can be formulated as described above for zosuquidar and Mylotarg, and can be included in kits, also as described above.
The zosuquidar, daunorubicin, and/or cytarabine can be to patients suffering from AML prior to confirmation of the P-gp expression or function, or to AML
patients other than newly diagnosed AML patients (e.g., relapsed AML patients). However, therapy is preferably administered to newly diagnosed AML patients. The administration route, amount administered, and frequency of administration can vary depending on the age of the patient, status as relapsed or newly diagnosed AML patient, and severity of the condition.
Contemplated amounts of zosuquidar for intravenous administration to treat newly diagnosed AML are from about 400 mg/day or less to about 1,600 mg/day or more, preferably from about 500, 600, or 700 mg/day to about 900, 1000, 1100, 1200, 1300, 1400, or 1500 mg/day, and most preferably 700 mg/day. In the course of a treatment regimen, the zosuquidar is preferably administered on two, three, or four separate days.
The dosage is preferably administered in intravenously continuously over the course of about 6 to about 90 hours, more preferably over the course of about 12, 18, 24, 30, 36, or 42 hours to about 54, 60, 66, 72, 78, or 84 hours, most preferably over about 24 hours, 48 hours, or 72 hours, depending upon the treatment regimen. Preferably the zosuquidar is administered on Day 1 of the treatment regimen. In certain embodiments, additional zosuquidar is administered on Day 2, on Days 2 and 3, or on Days 2, 15, and 16.
However, in certain embodiments, one, two, or three or more additional doses can be administered on other days of the treatment regimen.
Contemplated amounts of daunorubicin for intravenous administration to treat newly diagnosed AML are from about 10 mg/m2/day or less to about 100 ing/m2/day or more administered at initiation of zosuquidar infusion or up to about 1, 2, 3, 4, 5, or 6 or more hours after initiation of zosuquidar infusion. The dosage is preferably administered intravenously at a rate of about 25 mg/m2/day or less to about 90 mg/m2/day or more, preferably about 30, 35, or 40 mg/m2/day or less to about 50, 55, 60, 65, 70, 75, 80, or 85 mg/m2 /day, and most preferably about 45 mg/mz/day continuously over the course of about 2 or 2.5 days to about 3.5 or 4 days, preferably about 3 days.
Contemplated amounts of cytarabine for intravenous administration to treat newly diagnosed AML patients are from about 10 mg/day or less to about 3,000 mg/day or more administered at initiation of zosuquidar infusion or after initiation of zosuquidar infusion.
The dosage is preferably administered intravenously at a rate of about 50 mg/m2/day or less to about 200 mg/m2/day or more, preferably 60, 70, 80, or 90 mg/m2/day or less to about 110, 120, 130, 140, 150, 160, 170, 180, or 190 ing/m2/day, and most preferably about 100 ing/m2/day continuously over the course of about 1, 2, 3, 4, 5, or 6 days up to about 8, 9, or 10 days or more, preferably over about 7 days.
A particularly preferred dosing regimen for newly diagnosed AML includes continuous intravenous administration of 550 mg of zosuquidar over 6 hours (3 days), continuous intravenous administration of cytarabine at a rate of 100 mg/m2/day (7 days), and intravenous administration of daunorubicin at a dose of 45 mg/m2/day (3 days), wherein infusion of daunorubicin is started 1 hour after initiation of zosuquidar infusion.
Another particularly preferred dosing regimen includes continuous intravenous administration (preferably about 1 to 24 hours in duration, more preferably about 6 to 24 hours in duration, most preferably about 24 hours in duration) of 500 to 700 mg/day of zosuquidar (3 days), continuous intravenous administration of cytarabine at a rate of 100 mg/m2/day (7 days), and intravenous administration of daunorubicin at a dose of 45 mg/m2/day (3 days), wherein infusion of daunorubicin is started 1 to 4 hours after initiation of zosuquidar infusion. While in the above described embodiments infusion of daunorubicin is started after a specified time period has lapsed after initiation of zosuquidar infusion, in other embodiments other start times can be preferred, e.g., immediately after or during initiation of zosuquidar infusion up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more hours after initiation of zosuquidar infusion.
While the above methods of the preferred embodiments have been discussed primarily in connection with the treatment of AML, the methods are also particularly efficacious when P-gp substrates are administered as chemotherapeutic agents in the treatment of other malignancies exhibiting some degree of P-gp expression. For example, such malignancies can include lymphomas, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, myeloma, lymphocytic leukemia, sarcoma, metastatic breast cancer, and most solid tumors. Chemotherapeutic agents that are P-gp substrates include, but are not limited to, anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone), vincas (e.g., vincristine, vinblastine, vinorelbine, vindesine), Topoisomerase-Il inhibitors (e.g., etoposide, teniposide), taxanes (e.g., paclitaxel, docetaxel), and others (e.g., Gleevec, Mylotarg, dactinomycin, mithramycin).
Efflux Assay A commonly used method for the detection of MDR1 functional activity is referred to as the "efflux assay." In this assay the tumor cells are incubated with a fluorescent dye such as DiOC2 or Rhodamine 123 to allow for accumulation of the dye.
The cells are then washed, a fraction of the cells are measured for dye content immediately or are placed on ice to obtain a baseline dye uptake control, and the remaining cells are recultured in the presence and absence of an MDR1 inhibitor, such as zosuquidar. Since zosuquidar inhibits MDR1, the dye will be retained by such treated cells, and with cells cultured in the absence of zosuquidar the dye will be eliminated (effluxed). Retention and elimination of the dye is quantified by flow cytometry. There is a second way to detect retention or elimination of the dye and it is called the "accumulation assay." The cells in this assay are incubated with dye in the presence and absence of an MDR1 inhibitor such as zosuquidar. At the end of the incubation period, the cells are washed and assessed for retention of dye by flow cytometry. The standard method for detection of MDR1 activity is by the efflux assay. As shown herein, the accumulation assay is superior to the standard efflux assay for the assessment of MDR1 status in cancer patients. However, the efflux assay can yield substantially improved signal to noise if the cells are allowed to accumulate dye in the presence of an MDR1 inhibitor such as zosuquidar.
Identification of the Distinct Advantage of the Accumulation Assay Over the Standard Efflux Assa s~g K562/R7 MDR1-positive and K562 MDR1-negative Cell Lines K562/R7 cells express MDR1 as a consequence of selection in the presence of doxorubicin. The parental K562 cell line does not express appreciable MDR1.
DiOC2 was the dye selected as the surrogate fluorescent marker for MDR1 substrate chemotherapeutic agents. The accumulation assay involved cells cultured at 5 x cells/ml, 0.5 ml/ culture volume, 60 ng/ml DiOC2, and incubation at 37 C for at least 30 and not longer than 90 minutes. The efflux assay involved culturing cells with 60 ng/ml DiOC2, washing the cells and reculturing as described for the accumulation assay. The cells are then analyzed for fluorescence by flow cytometry.
The dosage is preferably administered intravenously at a rate of about 50 mg/m2/day or less to about 200 mg/m2/day or more, preferably 60, 70, 80, or 90 mg/m2/day or less to about 110, 120, 130, 140, 150, 160, 170, 180, or 190 ing/m2/day, and most preferably about 100 ing/m2/day continuously over the course of about 1, 2, 3, 4, 5, or 6 days up to about 8, 9, or 10 days or more, preferably over about 7 days.
A particularly preferred dosing regimen for newly diagnosed AML includes continuous intravenous administration of 550 mg of zosuquidar over 6 hours (3 days), continuous intravenous administration of cytarabine at a rate of 100 mg/m2/day (7 days), and intravenous administration of daunorubicin at a dose of 45 mg/m2/day (3 days), wherein infusion of daunorubicin is started 1 hour after initiation of zosuquidar infusion.
Another particularly preferred dosing regimen includes continuous intravenous administration (preferably about 1 to 24 hours in duration, more preferably about 6 to 24 hours in duration, most preferably about 24 hours in duration) of 500 to 700 mg/day of zosuquidar (3 days), continuous intravenous administration of cytarabine at a rate of 100 mg/m2/day (7 days), and intravenous administration of daunorubicin at a dose of 45 mg/m2/day (3 days), wherein infusion of daunorubicin is started 1 to 4 hours after initiation of zosuquidar infusion. While in the above described embodiments infusion of daunorubicin is started after a specified time period has lapsed after initiation of zosuquidar infusion, in other embodiments other start times can be preferred, e.g., immediately after or during initiation of zosuquidar infusion up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more hours after initiation of zosuquidar infusion.
While the above methods of the preferred embodiments have been discussed primarily in connection with the treatment of AML, the methods are also particularly efficacious when P-gp substrates are administered as chemotherapeutic agents in the treatment of other malignancies exhibiting some degree of P-gp expression. For example, such malignancies can include lymphomas, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, myeloma, lymphocytic leukemia, sarcoma, metastatic breast cancer, and most solid tumors. Chemotherapeutic agents that are P-gp substrates include, but are not limited to, anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone), vincas (e.g., vincristine, vinblastine, vinorelbine, vindesine), Topoisomerase-Il inhibitors (e.g., etoposide, teniposide), taxanes (e.g., paclitaxel, docetaxel), and others (e.g., Gleevec, Mylotarg, dactinomycin, mithramycin).
Efflux Assay A commonly used method for the detection of MDR1 functional activity is referred to as the "efflux assay." In this assay the tumor cells are incubated with a fluorescent dye such as DiOC2 or Rhodamine 123 to allow for accumulation of the dye.
The cells are then washed, a fraction of the cells are measured for dye content immediately or are placed on ice to obtain a baseline dye uptake control, and the remaining cells are recultured in the presence and absence of an MDR1 inhibitor, such as zosuquidar. Since zosuquidar inhibits MDR1, the dye will be retained by such treated cells, and with cells cultured in the absence of zosuquidar the dye will be eliminated (effluxed). Retention and elimination of the dye is quantified by flow cytometry. There is a second way to detect retention or elimination of the dye and it is called the "accumulation assay." The cells in this assay are incubated with dye in the presence and absence of an MDR1 inhibitor such as zosuquidar. At the end of the incubation period, the cells are washed and assessed for retention of dye by flow cytometry. The standard method for detection of MDR1 activity is by the efflux assay. As shown herein, the accumulation assay is superior to the standard efflux assay for the assessment of MDR1 status in cancer patients. However, the efflux assay can yield substantially improved signal to noise if the cells are allowed to accumulate dye in the presence of an MDR1 inhibitor such as zosuquidar.
Identification of the Distinct Advantage of the Accumulation Assay Over the Standard Efflux Assa s~g K562/R7 MDR1-positive and K562 MDR1-negative Cell Lines K562/R7 cells express MDR1 as a consequence of selection in the presence of doxorubicin. The parental K562 cell line does not express appreciable MDR1.
DiOC2 was the dye selected as the surrogate fluorescent marker for MDR1 substrate chemotherapeutic agents. The accumulation assay involved cells cultured at 5 x cells/ml, 0.5 ml/ culture volume, 60 ng/ml DiOC2, and incubation at 37 C for at least 30 and not longer than 90 minutes. The efflux assay involved culturing cells with 60 ng/ml DiOC2, washing the cells and reculturing as described for the accumulation assay. The cells are then analyzed for fluorescence by flow cytometry.
Figure 1 presents typical histograms of K562/R7. The upper panel shows autofluorescence, i.e., cells cultured in the absence of DiOC2. K562/R7 cells exhibit such strong MDR1 activity and, as shown in the middle panel, accumulated minimal dye in the absence of zosuquidar. However, the cells could be forced to accumulate dye if cultured in the presence of zosuquidar (bottom panel). This illustrates the differences between the typical efflux and accumulation assays. In the typical efflux assay, the amount of dye ultimately loaded into the cells reflects the equilibrium between accumulation and efflux processes. In the accumulation assay with zosuquidar present, the amount of dye ultimately loaded into the cells reflects only influx since efflux is inhibited.
The data are typically expressed as ratios of mean fluorescence intensity (MFI) of zosuquidar-treated cultures divided by the MFI of untreated cultures. In the accumulation assay, the inhibitory effects of zosuquidar on K562/R7 MDR1 function were clearly evident as indicated by' the inhibition ratio of 15.6. In the efflux assay, assuming complete elimination of the dye to autofluorescence levels, a ratio of 1.55 would be observed, which is considered dim or negative MDRI activity with the standard efflux assay. Thus, as will be addressed subsequently, it is quite possible that leukemia cells with very high MDR1 activity could similarly be misclassified with the standard efflux assay.
The Distinct Advantage of the Accumulation Assay over the Standard Efflux Assay Can Be Observed with Leukemia cells A coinparison was conducted between the accumulation and efflux assays with leukemia cells. Figure 2 presents a graphic depiction of the data. Negative or "dim"
results are indicated by samples with ratios to the left of the vertical line at a ratio of 1.55.
A number of samples exhibited comparable ratios in the two assays. However, some samples exhibited what would be considered dim or negative MDR1 functional activity in the efflux assay, but rather substantial activity in the accumulation assay.
While not wishing to be bound by theory, a possible explanation for this observation could be that in the accumulation assay some highly active MDR1-positive cells, like K562/R7 cells (referring to Figure 1), can be forced to accumulate dye provided that zosuquidar is present. In the efflux assay, where zosuquidar is not present during dye loading, these highly active cells would not accumulate enough dye to be identified as effluxing during the secondary efflux stage of that assay.
The data are typically expressed as ratios of mean fluorescence intensity (MFI) of zosuquidar-treated cultures divided by the MFI of untreated cultures. In the accumulation assay, the inhibitory effects of zosuquidar on K562/R7 MDR1 function were clearly evident as indicated by' the inhibition ratio of 15.6. In the efflux assay, assuming complete elimination of the dye to autofluorescence levels, a ratio of 1.55 would be observed, which is considered dim or negative MDRI activity with the standard efflux assay. Thus, as will be addressed subsequently, it is quite possible that leukemia cells with very high MDR1 activity could similarly be misclassified with the standard efflux assay.
The Distinct Advantage of the Accumulation Assay over the Standard Efflux Assay Can Be Observed with Leukemia cells A coinparison was conducted between the accumulation and efflux assays with leukemia cells. Figure 2 presents a graphic depiction of the data. Negative or "dim"
results are indicated by samples with ratios to the left of the vertical line at a ratio of 1.55.
A number of samples exhibited comparable ratios in the two assays. However, some samples exhibited what would be considered dim or negative MDR1 functional activity in the efflux assay, but rather substantial activity in the accumulation assay.
While not wishing to be bound by theory, a possible explanation for this observation could be that in the accumulation assay some highly active MDR1-positive cells, like K562/R7 cells (referring to Figure 1), can be forced to accumulate dye provided that zosuquidar is present. In the efflux assay, where zosuquidar is not present during dye loading, these highly active cells would not accumulate enough dye to be identified as effluxing during the secondary efflux stage of that assay.
Figure 3 presents an example of these phenomena in a leukemia cell sample. The cells were loaded for the efflux assay and eitlier placed on ice (upper left panel, baseline control) or allowed to efflux in the absence (middle left panel) or presence of zosuquidar (lower left panel). The efflux ratio was 2.6. The maximum amount of dye in the loaded cells yielded a MFI = 121. However, as shown in the lower right panel, loading in the presence of zosuquidar (accumulation) yielded a MFI = 907 and a ratio = 7.5.
The data can be interpreted as demonstrating, as with K562/R7 cells, that leukemia cells with high MDR1 activity only accumulate substantial amounts of dye when cultured in the presence of an MDRl inhibitor.
The Use of Zosuquidar during Dye Loading Can Yield a Highly Sensitive Efflux Assay Figure 4 presents the efflux characteristics of K562/R7 cells which had been loaded with 40 ng/ml DiOC2 in the presence of 200 ng/ml zosuquidar for 60 minutes.
The loaded and washed cells were cultured at 37 C in 0.5 ml lacking or containing the indicated concentrations of drug for the indicated amount of time. Control cells were placed on ice immediately after loading and, as indicated by the symbol to the far right at MFI = 1172, the cells had been loaded with dye. Incubation (efflux) in the presence of zosuquidar inhibited dye release in a concentration-dependent manner which was basically independent of incubation period. Significantly, in contrast to the low efflux ratio (1.55) illustrated in Figure 1 using the standard efflux methods, loading cells in the presence of zosuquidar yielded an efflux assay with a high efflux ratio =
26.8.
Discussion of Results As shown herein, the standard efflux method suffers from a lack of sensitivity when leukemia cells with very high MDR1 activity are tested. The amount of dye present in cells to be tested in the standard efflux assay reflects the equilibrium between accumulation and efflux during the loading period. The poor sensitivity of the standard efflux assay results from the high efflux rate of some cancer samples yielding poorly loaded cells for the test. In other words, the presence of leukemia cells with the highest MDR1 activity would be missed with the standard efflux assay because they were poorly loaded with dye. The present results show that the accumulation assay, which reflects accumulation which is independent of efflux (inhibited by zosuquidar), frequently yielded a much more sensitive assay for the assessment of leukemia cells with high activity. Furthermore, by loading such cells in the presence of an MDR1 inhibitor such as zosuquidar, an enhanced efflux assay was achieved (Figure 1 vs. Figure 4).
These novel observations indicate that the use of the accumulation assay, or the efflux assay with cells loaded with dye in the presence of zosuquidar, are far superior methods over the standard efflux assay, for the assessment of MDRl status in patients with cancer.
All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and are hereby made a part of this specification. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
The term "comprising" as used herein is synonymous with "including,"
"containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention.
The data can be interpreted as demonstrating, as with K562/R7 cells, that leukemia cells with high MDR1 activity only accumulate substantial amounts of dye when cultured in the presence of an MDRl inhibitor.
The Use of Zosuquidar during Dye Loading Can Yield a Highly Sensitive Efflux Assay Figure 4 presents the efflux characteristics of K562/R7 cells which had been loaded with 40 ng/ml DiOC2 in the presence of 200 ng/ml zosuquidar for 60 minutes.
The loaded and washed cells were cultured at 37 C in 0.5 ml lacking or containing the indicated concentrations of drug for the indicated amount of time. Control cells were placed on ice immediately after loading and, as indicated by the symbol to the far right at MFI = 1172, the cells had been loaded with dye. Incubation (efflux) in the presence of zosuquidar inhibited dye release in a concentration-dependent manner which was basically independent of incubation period. Significantly, in contrast to the low efflux ratio (1.55) illustrated in Figure 1 using the standard efflux methods, loading cells in the presence of zosuquidar yielded an efflux assay with a high efflux ratio =
26.8.
Discussion of Results As shown herein, the standard efflux method suffers from a lack of sensitivity when leukemia cells with very high MDR1 activity are tested. The amount of dye present in cells to be tested in the standard efflux assay reflects the equilibrium between accumulation and efflux during the loading period. The poor sensitivity of the standard efflux assay results from the high efflux rate of some cancer samples yielding poorly loaded cells for the test. In other words, the presence of leukemia cells with the highest MDR1 activity would be missed with the standard efflux assay because they were poorly loaded with dye. The present results show that the accumulation assay, which reflects accumulation which is independent of efflux (inhibited by zosuquidar), frequently yielded a much more sensitive assay for the assessment of leukemia cells with high activity. Furthermore, by loading such cells in the presence of an MDR1 inhibitor such as zosuquidar, an enhanced efflux assay was achieved (Figure 1 vs. Figure 4).
These novel observations indicate that the use of the accumulation assay, or the efflux assay with cells loaded with dye in the presence of zosuquidar, are far superior methods over the standard efflux assay, for the assessment of MDRl status in patients with cancer.
All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and are hereby made a part of this specification. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
The term "comprising" as used herein is synonymous with "including,"
"containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention.
Claims (86)
1. A method of treating a cancer, the method comprising the steps of:
determining P-glycoprotein expression or P-glycoprotein function in the cancer cells;
selecting a treatment for the patient, based on the P-glycoprotein expression; and administering the treatment, whereby the cancer is treated.
determining P-glycoprotein expression or P-glycoprotein function in the cancer cells;
selecting a treatment for the patient, based on the P-glycoprotein expression; and administering the treatment, whereby the cancer is treated.
2. The method of claim 1, wherein P-glycoprotein expression is determined by an antibody assay, and wherein the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when positive P-glycoprotein expression is observed in at least about 10% of the cells tested in the antibody assay.
3. The method of claim 2, wherein positive P-glycoprotein expression is observed in from about 10% to about 25% of the cells tested in the antibody assay.
4. The method of claim 1, wherein P-glycoprotein expression is determined by an antibody assay, and wherein the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when positive P-glycoprotein expression is observed for less than about 10% of the cells tested in the antibody assay.
5. The method of claim 1, wherein P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and wherein the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when, in the P-glycoprotein dye accumulation assay, a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is at least about 1:1.2.
6. The method of claim 5, wherein a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is from about 1:1.2 to about 1:1.5.
7. The method of claim 1, wherein P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and wherein the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye accumulation assay, a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is less than about 1:1.2.
8. The method of claim 1, wherein P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and wherein the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is at least about 1:1.2.
9. The method of claim 8, wherein an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is from about 1:1.2 to about 1:1.5.
10. The method of claim 1, wherein P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and wherein the step of selecting the treatment and administering the treatment comprises administering a P-glycoprotein efflux pump inhibitor in combination with a chemotherapeutic agent that is a substrate for P-glycoprotein efflux when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is at least about 30% higher than that contained in baseline control cells, and wherein cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels at least about 30% higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
11. The method of claim 10, wherein an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is from about 30% to about 50% higher than that contained in baseline control cells, and wherein cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels from about 30% to about 50% higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
12. The method of claim 1, wherein P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and wherein the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is less than about 1:1.2.
13. The method of claim 1, wherein P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and wherein the step of selecting the treatment and administering the treatment comprises administering a chemotherapeutic agent that is a substrate for P-glycoprotein efflux in the absence of a P-glycoprotein efflux pump inhibitor when, in the P-glycoprotein dye efflux assay, an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is less than about 30%
higher than that contained in baseline control cells, and wherein cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels less than about 30%
higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
higher than that contained in baseline control cells, and wherein cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels less than about 30%
higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
14. The method of claim 1, wherein the P-glycoprotein efflux pump inhibitor is selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene.
15. The method of claim 1, wherein the cancer is acute myelogenous leukemia.
16. The method of claim 1, wherein the cancer is a carcinoma.
17. The method of claim 16, wherein the carcinoma is breast cancer.
18. The method of claim 16, wherein the carcinoma is ovarian cancer.
19. The method of claim 1, wherein the cancer is a sarcoma.
20. The method of claim 1, wherein the cancer is a hematologic malignancy.
21. The method of claim 20, wherein the hematologic malignancy is selected from the group consisting of acute lymphoblastic leukemia, chronic myeloid leukemia, plasma cell dyscrasias, lymphoma, and myelodysplasia.
22. The method of claim 1, wherein the chemotherapeutic agent is an anthracycline.
23. The method of claim 22, wherein the anthracycline is selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, and mitoxantrone.
24. The method of claim 1, wherein the chemotherapeutic agent is a Topoisomerase-II inhibitor.
25. The method of claim 24, wherein the Topoisomerase-II inhibitor is etoposide or teniposide.
26. The method of claim 1, wherein the chemotherapeutic agent is a vinca.
27. The method of claim 26, wherein the vinca is selected from the group consisting of vincristine, vinblastine, vinorelbine, and vindesine.
28. The method of claim 1, wherein the chemotherapeutic agent is a taxane.
29. The method of claim 28, wherein the taxane is paclitaxel or docetaxel.
30. The method of claim 1, wherein the chemotherapeutic agent is selected from the group consisting of gleevec, dactinomycin, bisantrene, mitoxantrone, actinomyocin D, mithomycin C, mitramycin, methotrexate, adriamycin, mitomycin, mithramycin, anthracene, and epipodophyllo-toxin.
31. A pharmaceutical kit, the kit comprising:
at least one dose of a P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene;
directions for conducting a diagnostic for determining P-glycoprotein expression or P-glycoprotein function associated with the cancer; and directions for administering the P-glycoprotein efflux pump inhibitor and a chemotherapeutic agent that is a substrate for P-glycoprotein efflux to the patient to treat the cancer when P-glycoprotein expression or P-glycoprotein function is positive.
at least one dose of a P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene;
directions for conducting a diagnostic for determining P-glycoprotein expression or P-glycoprotein function associated with the cancer; and directions for administering the P-glycoprotein efflux pump inhibitor and a chemotherapeutic agent that is a substrate for P-glycoprotein efflux to the patient to treat the cancer when P-glycoprotein expression or P-glycoprotein function is positive.
32. A method of treating a condition in a patient by administering a therapeutic agent that is a substrate for P-glycoprotein efflux, the method comprising the steps of:
determining P-glycoprotein expression or P-glycoprotein function; and administering the therapeutic agent in combination with a P-glycoprotein efflux pump inhibitor when P-gp expression is positive.
determining P-glycoprotein expression or P-glycoprotein function; and administering the therapeutic agent in combination with a P-glycoprotein efflux pump inhibitor when P-gp expression is positive.
33. The method of claim 32, wherein P-glycoprotein expression is determined by an antibody assay, and wherein positive P-glycoprotein expression is observed in at least about 10% of the cells tested in the antibody assay.
34. The method of claim 33, wherein P-glycoprotein expression is determined by an antibody assay, and wherein positive P-glycoprotein expression is observed in from about 10% to about 25% of the cells tested in the antibody assay.
35. The method of claim 32, wherein P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and wherein a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is at least about 1:1.2.
36. The method of claim 35, wherein P-glycoprotein function is determined by a P-glycoprotein dye accumulation assay, and wherein a ratio of dye taken up by cells in the presence of the P-glycoprotein efflux pump inhibitor to dye taken up by cells cultured in the absence of the P-glycoprotein efflux pump inhibitor is from about 1:1.2 to about 1:1.5.
37. The method of claim 32, wherein P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and wherein an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is at least about 1:1.2.
38. The method of claim 37, wherein P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and wherein an amount of dye eliminated from the cells in the presence of the P-glycoprotein efflux pump inhibitor divided by an amount of dye eliminated in the absence of P-glycoprotein efflux pump inhibitor is from about 1:1.2 to about 1:1.5.
39. The method of claim 32, wherein P-glycoprotein function is determined by a P-glycoprotein dye efflux assay, and wherein an amount of dye eliminated from the cells in an absence of the P-glycoprotein efflux pump inhibitor is at least about 30% higher than that contained in baseline control cells, and wherein cells incubated in a presence of the P-glycoprotein efflux pump inhibitor have dye levels at least about 30%
higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
higher than cells cultured in an absence of the P-glycoprotein efflux pump inhibitor.
40. The method of claim 32, wherein the P-glycoprotein efflux pump inhibitor is selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene.
41. The method of claim 32, wherein the therapeutic agent comprises an immunosuppressant.
42. The method of claim 41, wherein the immunosuppressant is selected from the group consisting of cyclosporine, cyclosporine A, and tacrolimus.
43. The method of claim 32, wherein the therapeutic agent comprises a steroid.
44. The method of claim 43, wherein the steroid is selected from the group consisting of dexamethasone, hydrocortisone, corticosterone, triamcinolone, aldosterone, and methylprednisolone.
45. The method of claim 32, wherein the therapeutic agent comprises an antiepileptic.
46. The method of claim 45, wherein the antiepileptic comprises phenytoin.
47. The method of claim 32, wherein the therapeutic agent comprises an antidepressant.
48. The method of claim 47, wherein the antidepressant is selected from the group consisting of citalopram, thioperidone, trazodone, trimipramine, amitriptyline, and phenothiazines.
49. The method of claim 32, wherein the therapeutic agent comprises an antipsychotic.
50. The method of claim 49, wherein the antipsychotic is selected from the group consisting of fluphenazine, haloperidol, thioridazine, and trimipramine.
51. The method of claim 32, wherein the therapeutic agent comprises a protease inhibitor.
52. The method of claim 51, wherein the protease inhibitor is selected from the group consisting of amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir.
53. The method of claim 32, wherein the therapeutic agent comprises a calcium blocker.
54. The method of claim 53, wherein the calcium blocker is selected from the group consisting of bepridil, diltiazem, flunarizine, lomerizine, secoverine, tamolarizine, verapamil, nicardipine, prenylamine, and fendiline.
55. The method of claim 32, wherein the therapeutic agent comprises a cardiac drug.
56. The method of claim 55, wherein the cardiac drug is selected from the group consisting of digoxin, diltiazem, verapamil, and talinolol.
57. A pharmaceutical kit, the kit comprising:
at least one dose of a P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene;
directions for conducting a diagnostic for determining a value for P-gp expression associated with a condition; and directions for administering the P-glycoprotein efflux pump inhibitor and a therapeutic agent that is a substrate for P-glycoprotein efflux to the patient to treat the condition when P-glycoprotein expression or P-glycoprotein function is positive.
at least one dose of a P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene;
directions for conducting a diagnostic for determining a value for P-gp expression associated with a condition; and directions for administering the P-glycoprotein efflux pump inhibitor and a therapeutic agent that is a substrate for P-glycoprotein efflux to the patient to treat the condition when P-glycoprotein expression or P-glycoprotein function is positive.
58. A method of treating a cancer in a patient, the method comprising the steps of:
conducting a P-glycoprotein efflux assay on the cancer cells in the presence of a P-glycoprotein efflux inhibitor, whereby a first value for P-glycoprotein function is obtained;
conducting a P-glycoprotein efflux assay on the cancer cells in the absence of a P-glycoprotein efflux inhibitor, whereby a second value for P-glycoprotein function is obtained;
comparing the first value and the second value for P-glycoprotein function, wherein the patient exhibits inhibitable P-glycoprotein efflux when the first value, is greater than the second value; and administering to the patient exhibiting inhibitable P-glycoprotein efflux the P-glycoprotein efflux inhibitor and a chemotherapeutic agent that is a substrate for P-gp efflux.
conducting a P-glycoprotein efflux assay on the cancer cells in the presence of a P-glycoprotein efflux inhibitor, whereby a first value for P-glycoprotein function is obtained;
conducting a P-glycoprotein efflux assay on the cancer cells in the absence of a P-glycoprotein efflux inhibitor, whereby a second value for P-glycoprotein function is obtained;
comparing the first value and the second value for P-glycoprotein function, wherein the patient exhibits inhibitable P-glycoprotein efflux when the first value, is greater than the second value; and administering to the patient exhibiting inhibitable P-glycoprotein efflux the P-glycoprotein efflux inhibitor and a chemotherapeutic agent that is a substrate for P-gp efflux.
59. The method of claim 58, wherein the patient exhibits inhibitable P-glycoprotein efflux when a ratio of the second value to the first value is greater than or equal to about 1:1.2.
60. The method of claim 58, wherein the patient exhibits inhibitable P-glycoprotein efflux when a ratio of the second value to the first value is from about 1:1.2 to about 1:1.5.
61. The method of claim 58, wherein the patient exhibits inhibitable P-glycoprotein efflux when the first value is at least about 30% higher than the second value.
62. The method of claim 58, wherein the patient exhibits inhibitable P-glycoprotein efflux when the first value is from about 30% to about 50% higher than the second value.
63. The method of claim 58, wherein the P-glycoprotein efflux pump inhibitor selected from the group consisting of zosuquidar, Tariquidar, and Tesmilifene.
64. The method of claim 58, wherein the step of determining a value for P-gp expression comprises conducting an assay, wherein the assay is selected based on the cancer.
65. The method of claim 58, wherein the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression comprises conducting a flow cytometry assay.
66. The method of claim 58, wherein the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression comprises conducting a radiolabeled drug assay.
67. The method of claim 58, wherein the cancer is a leukemia or a lymphoma, and wherein the step of determining a value for P-gp expression comprises conducting a solid phase immunoassay that measure a cell-associated drug with an anti-drug antibody.
68. The method of claim 58, wherein the cancer is a solid tumor, and wherein the step of determining a value for P-gp expression comprises conducting an immunocytochemistry assay.
69. The method of claim 58, wherein the cancer is a solid tumor, and wherein the step of determining a value for P-gp expression comprises conducting an immunohistochemistry assay.
70. The method of claim 58, wherein the assay quantifies P-gp function.
71. The method of claim 58, wherein the cancer is acute myelogenous leukemia.
72. The method of claim 58, wherein the cancer is a carcinoma.
73. The method of claim 72, wherein the carcinoma is breast cancer.
74. The method of claim 72, wherein the carcinoma is ovarian cancer.
75. The method of claim 58, wherein the cancer is a sarcoma.
76. The method of claim 58, wherein the cancer is a hematologic malignancy.
77. The method of claim 76, wherein the hematologic malignancy is selected from the group consisting of acute lymphoblastic leukemia, chronic myeloid leukemia, plasma cell dyscrasias, lymphoma, and myelodysplasia.
78. The method of claim 58, wherein the chemotherapeutic agent is an anthracycline.
79. The method of claim 78, wherein the anthracycline is selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, and mitoxantrone.
80. The method of claim 58, wherein the chemotherapeutic agent is a Topoisomerase-II inhibitor.
81. The method of claim 80, wherein the Topoisomerase-II inhibitor is etoposide or teniposide.
82. The method of claim 58, wherein the chemotherapeutic agent is a vinca.
83. The method of claim 82, wherein the vinca is selected from the group consisting of vincristine, vinblastine, vinorelbine, and vindesine.
84. The method of claim 58, wherein the chemotherapeutic agent is a taxane.
85. The method of claim 84, wherein the taxane is paclitaxel or docetaxel.
86. The method of claim 58, wherein the chemotherapeutic agent is selected from the group consisting of Gleevec, dactinomycin, mitomycin, mithramycin, and Mylotarg.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69691305P | 2005-07-06 | 2005-07-06 | |
US60/696,913 | 2005-07-06 | ||
US72682705P | 2005-10-14 | 2005-10-14 | |
US60/726,827 | 2005-10-14 | ||
US11/418,323 US20070009534A1 (en) | 2005-07-06 | 2006-05-03 | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
US11/418,399 US20070009535A1 (en) | 2005-07-06 | 2006-05-03 | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
US11/417,984 US20070009533A1 (en) | 2005-07-06 | 2006-05-03 | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
US11/418,323 | 2006-05-03 | ||
US11/417,984 | 2006-05-03 | ||
US11/418,399 | 2006-05-03 | ||
PCT/US2006/026035 WO2007008499A1 (en) | 2005-07-06 | 2006-06-30 | Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2614392A1 true CA2614392A1 (en) | 2007-01-18 |
Family
ID=37637469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002614392A Abandoned CA2614392A1 (en) | 2005-07-06 | 2006-06-30 | Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1899728A4 (en) |
AU (1) | AU2006269501A1 (en) |
CA (1) | CA2614392A1 (en) |
WO (1) | WO2007008499A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019147089A1 (en) * | 2018-01-26 | 2019-08-01 | 재단법인 대구경북첨단의료산업진흥재단 | Pharmaceutical composition for preventing or treating cancer comprising, as active ingredient, calcium channel inhibitor or pharmaceutically acceptable salt thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773280A (en) * | 1992-03-20 | 1998-06-30 | The Board Of Trustees Of The University Of Illinois | Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses |
US6277655B1 (en) * | 1994-10-13 | 2001-08-21 | Solvo Biotechnology | Assay and reagent kit for evaluation of multi-drug resistance in cells |
WO2001084148A2 (en) * | 2000-04-28 | 2001-11-08 | Sangamo Biosciences, Inc. | Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions |
-
2006
- 2006-06-30 AU AU2006269501A patent/AU2006269501A1/en not_active Abandoned
- 2006-06-30 CA CA002614392A patent/CA2614392A1/en not_active Abandoned
- 2006-06-30 WO PCT/US2006/026035 patent/WO2007008499A1/en active Application Filing
- 2006-06-30 EP EP06786249A patent/EP1899728A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2007008499A1 (en) | 2007-01-18 |
EP1899728A4 (en) | 2009-03-25 |
AU2006269501A1 (en) | 2007-01-18 |
EP1899728A1 (en) | 2008-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070009533A1 (en) | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism | |
Ng et al. | Expression of P-glycoprotein in hepatocellular carcinoma: a determinant of chemotherapy response | |
RU2480211C2 (en) | Method of treating breast cancer with compound of 4-iodine-3-nitrobenzamine in combination with anticancer agents | |
AU2018214086B2 (en) | Use of eribulin in the treatment of breast cancer | |
US20080214606A1 (en) | Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells | |
JP2022082565A (en) | Methods for treating cancer | |
US20070009535A1 (en) | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism | |
US20220387618A1 (en) | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate | |
US20070010466A1 (en) | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer | |
US11376259B2 (en) | Targeted treatment of mature T-cell lymphoma | |
EP3145509A1 (en) | Methods of treating pr-positive, luminal a breast cancer with pi3k inhibitor, pictilisib | |
US20070009532A1 (en) | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar | |
US20070009534A1 (en) | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism | |
CN113939297A (en) | Bifluoroalkyl-1, 4-benzodiazepinone compounds for the treatment of Notch activated breast cancer | |
CA2614392A1 (en) | Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism | |
WO2016184793A1 (en) | Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma | |
WO2007008490A2 (en) | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer | |
CA3180522A1 (en) | Therapeutic methods for preventing tumor metastasis and tumor recurrence | |
Xu et al. | In vitro chemosensitivity assay of ascites in epithelial ovarian cancer. | |
JP2022532597A (en) | How to treat cancer with CHK1 inhibitors | |
WO2023192291A2 (en) | Indolium compounds for treating cancer | |
Fröbom | Translational Investigations of Novel and Current Antitumoral Therapies in Gastrointestinal Stromal Tumors | |
CN111840274A (en) | Application of bavalomycin A1 in preparation of anti-liver cancer active drug for enhancing 7-desoxynarciclovir | |
EP1898946A1 (en) | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar | |
WO2012011485A1 (en) | Method for prediction of therapeutic effect of chemotherapy on breast cancer patient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |